Reference
1.
GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. The Lancet. 2024;404(10459):1199-1226. doi:10.1016/S0140-6736(24)01867-1
4.
Abubakar U, Al-Anazi M, Alanazi Z, Rodríguez-Baño J. Impact of COVID-19 pandemic on multidrug resistant gram positive and gram negative pathogens: A systematic review. Journal of Infection and Public Health. 2023;16(3):320-331. doi:10.1016/j.jiph.2022.12.022
5.
Kam KM, Luey KY, Fung SM, Yiu PP, Harden TJ, Cheung MM. Emergence of multiple-antibiotic-resistant Streptococcus pneumoniae in Hong Kong. Antimicrobial Agents and Chemotherapy. 1995;39(12):2667-2670. doi:10.1128/aac.39.12.2667
6.
Ho PL, Yuen KY, Yam WC, Wong SY, Luk WK. Changing patterns of susceptibilities of blood, urinary and respiratory pathogens in Hong Kong. Journal of Hospital Infection. 1995;31(4):305-317. doi:10.1016/0195-6701(95)90209-0
7.
French GL, Ling J, Ling T, Hul YW. Susceptibility of Hong Kong isolates of methicillin-resistant Staphylococcus aureus to antimicrobial agents. Journal of Antimicrobial Chemotherapy. 1988;21(5):581-588. doi:10.1093/jac/21.5.581
8.
Cheng AF, French GL. Methicillin-resistant Staphylococcus aureus bacteraemia in Hong Kong. Journal of Hospital Infection. 1988;12(2):91-101. doi:10.1016/0195-6701(88)90131-4
9.
Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. Diagnostic Microbiology and Infectious Disease. 1992;15(2 Suppl):37S-42S. doi:https://doi.org/10.1016/0732-8893(92)90006-F
10.
European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe – Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017. ECDC; 2018. https://www.ecdc.europa.eu/en/publications-data
/surveillance-antimicrobial-resistance-europe-2017
11.
World Health Organization. Health and economic impacts of antimicrobial resistance in the Western Pacific Region, 2020-2030. World Health Organization; 2023. https://www.who.int/publications/i/item/9789290620112
12.
Cheng VCC, Wong SCY, Ho PL, Yuen KY. Strategic measures for the control of surging antimicrobial resistance in Hong Kong and mainland of China. Emerging Microbes & Infections. 2015;4(1):1-13. doi:10.1038/emi.2015.8
13.
Ma ESK, Kung KH, Chen H. Combating antimicrobial resistance during the COVID-19 pandemic. Hong Kong Medical Journal. 2021;27(6):396-398. doi:10.12809/hkmj215124
14.
Wong SC, Chau PH, So SYC, Chiu KHY, Yuen LLH, AuYeung CHY, et al. Epidemiology of multidrug-resistant organisms before and during COVID-19 in Hong Kong. Infection Prevention in Practice. 2023;5(2):100286. doi:10.1016/j.infpip.2023.100286
15.
Centre for Health Protection, Department of Health, the Government of the Hong Kong Special Administrative Region. Hong Kong Strategy and Action Plan on Antimicrobial Resistance 2023 to 2027. Published online December 2022. Accessed December 20, 2024. https://www.chp.gov.hk/en/static/49301.html
17.
Long SW, Olsen RJ, Mehta SC, Palzkill T, Cernoch PL, Perez KK, et al. PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrobial Agents and Chemotherapy. 2014;58(11):6668-6674. doi:10.1128/AAC.03622-14
18.
Buck JM, Como-Sabetti K, Harriman KH, Danila RN, Boxrud DJ, Glennen A, et al. Community-associated methicillin-resistant Staphylococcus aureus, Minnesota, 2000–2003. Emerging Infectious Diseases. 2005;11:1532. doi:10.3201/eid1110.050141
19.
Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clinical Infectious Diseases. 2011;52(3):e18-e55. doi:10.1093/cid/ciq146
20.
Corey GR. Staphylococcus aureus Bloodstream Infections: Definitions and Treatment. Clinical Infectious Diseases. 2009;48(Supplement 4):S254-S259. doi:10.1086/598186
21.
Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrobial Agents and Chemotherapy. 2010;54(8):3271-3279. doi:10.1128/AAC.01044-09
22.
Ho PL, Chow KH, Lo PY, Lee KF, Lai EL. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus associated with spread of the ST45 lineage in Hong Kong. Diagnostic Microbiology and Infectious Disease. 2009;64(2):131-137. doi:10.1016/j.diagmicrobio.2009.01.030
23.
Luk S, Ho AY, Ng TK, Tsang IH, Chan EH, Choi KW, et al. Prevalence, prediction, and clonality of methicillin-resistant Staphylococcus aureus carriage at admission to medical units in Hong Kong, China. Infection Control & Hospital Epidemiology. 2014;35(1):42-48. doi:10.1086/674393
24.
Wong SC, Chen JHK, So SYC, Ho PL, Yuen KY, Cheng VCC. Gastrointestinal colonization of meticillin-resistant Staphylococcus aureus: an unrecognized burden upon hospital infection control. Journal of Hospital Infection. 2022;121:65-74. doi:10.1016/j.jhin.2021.12.016
25.
Wong SC, Chen JHK, Yuen LLH, Chan VWM, AuYeung CHY, Leung SSM, et al. Air dispersal of meticillin-resistant Staphylococcus aureus in residential care homes for the elderly: implications for transmission during the COVID-19 pandemic. Journal of Hospital Infection. 2022;123:52-60. doi:10.1016/j.jhin.2022.02.012
26.
Centre for Health Protection, Department of Health, the Government of the Hong Kong Special Administrative Region. Detection of Mycoplasma pneumoniae in respiratory specimens in 2023. Published online 2023. Accessed December 20, 2024. https://www.chp.gov.hk/en/statistics/data/10/641/642/7030.html
27.
Ho PL, Tse CW, Mak GC, Chow KH, Ng TK. Community-acquired methicillin-resistant Staphylococcus aureus arrives in Hong Kong. Journal of Antimicrobial Chemotherapy. 2004;54(4):845-846. doi:10.1093/jac/dkh426
28.
Tsang S. Review of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection in Hong Kong, 2012-2015. Communicable Diseases Watch. 2015;12(23):114-116. http://www.chp.gov.hk/files/pdf/cdw_compendium_2015.pdf
29.
Ho PL, Chuang SK, Choi YF, Lee RA, Lit AC, Ng TK, et al. Community-associated methicillin-resistant and methicillin-sensitive Staphylococcus aureus: skin and soft tissue infections in Hong Kong. Diagnostic Microbiology and Infectious Disease. 2008;61(3):245-250. doi:10.1016/j.diagmicrobio.2007.12.015
30.
Leung Y, Lai RW, Chan AC, Lo JY, Ho P, Wong MM, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus infection in Hong Kong. Journal of Infection. 2012;64(5):494-499. doi:10.1016/j.jinf.2012.02.009
31.
Cheng VC, Lau YK, Lee KL, Yiu KH, Chan KH, Ho PL, et al. Fatal co-infection with swine origin influenza virus A/H1N1 and community-acquired methicillin-resistant Staphylococcus aureus. Journal of Infection. 2009;59(5):366-370. doi:10.1016/j.jinf.2009.08.021
32.
Murray RJ, Robinson JO, White JN, Hughes F, Coombs GW, Pearson JC, et al. Community-acquired pneumonia due to Pandemic A(H1N1)2009 influenza virus and methicillin resistant Staphylococcus aureus co-infection. PLOS one. 2010;5(1):e8705. doi:10.1371/journal.pone.0008705
33.
Obando I, Valderrabanos ES, Millan JA, Neth OW. Necrotising pneumonia due to influenza A (H1N1) and community-acquired methicillin-resistant Staphylococcus aureus clone USA300: successful management of the first documented paediatric case. Archives of Disease in Childhood. 2010;95(4):305-306. doi:10.1136/adc.2009.175281
34.
Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. Clinical Microbiology and Infection. 2010;16(6):555-562. doi:10.1111/j.1469-0691.2010.03214.x
35.
Chuang VWM, Tsang DNC, Lam JKS, Lam RKW, Ng WH. An active surveillance study of vancomycin-resistant Enterococcus in Queen Elizabeth Hospital, Hong Kong. Hong Kong Medical Journal. 2005;11(6):463. https://www.hkmj.org/abstracts/v11n6/463.htm
36.
Ho PL. Carriage of methicillin-resistant Staphylococcus aureus, ceftazidime-resistant Gram-negative bacilli, and vancomycin-resistant enterococci before and after intensive care unit admission. Critical Care Medicine. 2003;31(4):1175-1182. doi:10.1097/01.CCM.0000059437.01924.97
37.
Cheng VC, Tai JW, Chau PH, Lai CK, Chuang VW, So SY, et al. Successful control of emerging vancomycin-resistant enterococci by territory-wide implementation of directly observed hand hygiene in patients in Hong Kong. American Journal of Infection Control. 2016;44(10):1168-1171. doi:10.1016/j.ajic.2016.03.050
38.
Willems RJ, Top J, Santen M van, Robinson DA, Coque TM, Baquero F, et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerging Infectious Diseases. 2005;11(6):821-828. doi:10.3201/eid1106.041204
39.
Top J, Willems R, Bonten M. Emergence of CC17 Enterococcus faecium: from commensal to hospital-adapted pathogen. FEMS Immunology and Medical Microbiology. 2008;52(3):297-308. doi:10.1111/j.1574-695X.2008.00383.x
40.
Regt MJA de, Wagen LE van der, Top J, Blok HEM, Hopmans TEM, Dekker AW, et al. High acquisition and environmental contamination rates of CC17 ampicillin-resistant Enterococcus faecium in a Dutch hospital. Journal of Antimicrobial Chemotherapy. 2008;62(6):1401-1406. doi:10.1093/jac/dkn390
41.
Valdezate S, Labayru C, Navarro A, Mantecón MA, Ortega M, Coque TM, et al. Large clonal outbreak of multidrug-resistant CC17 ST17 Enterococcus faecium containing Tn5382 in a Spanish hospital. Journal of Antimicrobial Chemotherapy. 2009;63(1):17-20. doi:10.1093/jac/dkn449
42.
Klare I, Konstabel C, Mueller-Bertling S, Werner G, Strommenger B, Kettlitz C, et al. Spread of ampicillin/vancomycin-resistant Enterococcus faecium of the epidemic-virulent clonal complex-17 carrying the genes esp and hyl in German hospitals. European Journal of Clinical Microbiology & Infectious Diseases. 2005;24(12):815-825. doi:10.1007/s10096-005-0056-0
43.
Panesso D, Reyes J, Rincon S, Diaz L, Galloway-Pena J, Zurita J, et al. Molecular epidemiology of vancomycin-resistant Enterococcus faecium: a prospective, multicenter study in South American hospitals. Journal of Clinical Microbiology. 2010;48(5):1562-1569. doi:10.1128/JCM.02526-09
44.
Hsieh YC, Lee WS, Ou TY, Hsueh PR. Clonal spread of CC17 vancomycin-resistant Enterococcus faecium with multilocus sequence type 78 (ST78) and a novel ST444 in Taiwan. European Journal of Clinical Microbiology & Infectious Diseases. 2010;29(1):25-30. doi:10.1007/s10096-009-0810-9
45.
Cairns KA, Udy AA, Peel TN, Abbott IJ, Dooley MJ, Peleg AY. Therapeutics for vancomycin-resistant enterococcal bloodstream infections. Clinical Microbiology Reviews. 2023;36(2):e00059-22. doi:10.1128/cmr.00059-22
46.
Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clinical Microbiology Reviews. 2005;18(4):657-686. doi:10.1128/CMR.18.4.657-686.2005
47.
Ho PL, Poon WW, Loke SL, Leung MS, Chow KH, Wong RC, et al. Community emergence of CTX-M type extended-spectrum β-lactamases among urinary Escherichia coli from women. Journal of Antimicrobial Chemotherapy. 2007;60(1):140-144. doi:10.1093/jac/dkm144
48.
Ho PL, Wong RC, Yip KS, Loke SL, Leung MS, Mak GC, et al. Antimicrobial resistance in Escherichia coli outpatient urinary isolates from women: emerging multidrug resistance phenotypes. Diagnostic Microbiology and Infectious Disease. 2007;59(4):439-445. doi:10.1016/j.diagmicrobio.2007.06.012
49.
Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, Cueto M de, Ríos MJ, et al. Bacteremia due to extended-spectrum β-lactamase–producing Escherichia coli in the CTX-M era: a new clinical challenge. Clinical Infectious Diseases. 2006;43(11):1407-1414. doi:10.1086/508877
50.
Kang CI, Cheong HS, Chung DR, Peck KR, Song JH, Oh MD, et al. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. European Journal of Clinical Microbiology & Infectious Diseases. 2008;27:85-88. doi:10.1007/s10096-007-0401-6
51.
Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Ruiz M, Pena C, et al. Community-onset bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: risk factors and prognosis. Clinical Infectious Diseases. 2010;50(1):40-48. doi:10.1086/649537
52.
Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clinical Infectious Diseases. 2009;49(5):682-690. doi:10.1086/604713
53.
Kwok KO, Chan E, Chung PH, Tang A, Wei WI, Zhu C, et al. Prevalence and associated factors for carriage of Enterobacteriaceae producing ESBLs or carbapenemase and methicillin-resistant Staphylococcus aureus in Hong Kong community. Journal of Infection. 2020;81(2):242-247. doi:10.1016/j.jinf.2020.05.033
54.
Ho PL, Chow KH, Lai EL, Lo WU, Yeung MK, Chan J, et al. Extensive dissemination of CTX-M-producing Escherichia coli with multidrug resistance to ’critically important’ antibiotics among food animals in Hong Kong, 2008-10. Journal of Antimicrobial Chemotherapy. 2011;66(4):765-768. doi:10.1093/jac/dkq539
55.
Ho PL, Lo WU, Yeung MK, Li Z, Chan J, Chow KH, et al. Dissemination of pHK01-like incompatibility group IncFII plasmids encoding CTX-M-14 in Escherichia coli from human and animal sources. Veterinary microbiology. 2012;158(1-2):172-179. doi:10.1016/j.vetmic.2012.02.004
56.
Centre for Health Protection, Department of Health, the Government of the Hong Kong Special Administrative Region. Antimicrobial Resistance Surveillance in Food – Raw meat (Data from a consultancy service administered by the Centre for Health Protection, Department of Health).
57.
Centre for Health Protection, Department of Health, the Government of the Hong Kong Special Administrative Region. Antimicrobial Resistance Surveillance in Food – Ready-to-eat (RTE) food. Published online 2024. Accessed December 20, 2024. https://www.chp.gov.hk/en/static/105699.html
58.
Ho PL, Chau PH, Yan MK, Chow KH, Chen JHK, Wong SCY, et al. High burden of extended-spectrum β-lactamase-positive Escherichia coli in geriatric patients. Journal of Medical Microbiology. 2014;63(6):878-883. doi:10.1099/jmm.0.068270-0
59.
Livermore DM, Andrews JM, Hawkey PM, Ho PL, Keness Y, Doi Y, et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? Journal of Antimicrobial Chemotherapy. 2012;67(7):1569-1577. doi:10.1093/jac/dks088
61.
ESCMID - European Society of Clinical Microbiology and Infectious Diseases 2024. EUCAST: Clinical breakpoints and dosing of antibiotics. https://www.eucast.org/clinical_breakpoints
62.
Ho PL, Chow KH, Lo WU, To KK, Cheng VC. Effect of applying the new Clinical and Laboratory Standards Institute ceftazidime and ceftriaxone susceptibility breakpoints for Escherichia coli in Hong Kong. International Journal of Antimicrobial Agents. 2011;37(3):270-271. doi:10.1016/j.ijantimicag.2010.11.016
63.
Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. The Lancet Infectious Diseases. 2009;9(4):228-236. doi:10.1016/S1473-3099(09)70054-4
64.
Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 2001;45(4):1151-1161. doi:10.1128/AAC.45.4.1151-1161.2001
65.
Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clinical Microbiology Reviews. 2007;20(3):440-458. doi:10.1128/CMR.00001-07
66.
Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York city: a new threat to our antibiotic armamentarium. Archives of Internal Medicine. 2005;165(12):1430-1435. doi:10.1001/archinte.165.12.1430
67.
Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrobial Agents and Chemotherapy. 2007;51(8):3026-3029. doi:10.1128/AAC.00299-07
68.
Cuzon G, Naas T, Demachy MC, Nordmann P. Plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece. Antimicrobial Agents and Chemotherapy. 2008;52(2):796-797. doi:10.1128/aac.01180-07
69.
Villegas MV, Lolans K, Correa A, Suarez CJ, Lopez JA, Vallejo M, et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrobial Agents and Chemotherapy. 2006;50(8):2880-2882. doi:10.1128/AAC.00186-06
70.
Pasteran FG, Otaegui L, Guerriero L, Radice G, Maggiora R, Rapoport M, et al. Klebsiella pneumoniae Carbapenemase–2, Buenos Aires, Argentina. Emerging Infectious Diseases. 2008;14(7):1178. doi:10.3201/eid1407.070826
71.
Peirano G, Seki LM, Val Passos VL, Pinto MC, Guerra LR, Asensi MD. Carbapenem-hydrolysing β-lactamase KPC-2 in Klebsiella pneumoniae isolated in Rio de Janeiro, Brazil. Journal of Antimicrobial Chemotherapy. 2009;63(2):265-268. doi:10.1093/jac/dkn484
72.
Wei ZQ, Du XX, Yu YS, Shen P, Chen YG, Li LJ. Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. Antimicrobial Agents and Chemotherapy. 2007;51(2):763-765. doi:10.1128/AAC.01053-06
73.
Cai JC, Zhou HW, Zhang R, Chen GX. Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli isolates possessing the plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC-2 in intensive care units of a Chinese hospital. Antimicrobial Agents and Chemotherapy. 2008;52(6):2014-2018. doi:10.1128/AAC.01539-07
74.
Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infection Control & Hospital Epidemiology. 2009;30(10):972-976. doi:10.1086/605922
75.
Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a new metallo-β-lactamase gene, bla NDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrobial Agents and Chemotherapy. 2009;53(12):5046-5054. doi:10.1128/AAC.00774-09
76.
Struelens MJ, Monnet DL, Magiorakos AP, O’Connor FS, Giesecke J, et al. New Delhi metallo-beta-lactamase 1–producing Enterobacteriaceae: emergence and response in Europe. Eurosurveillance. 2010;15(46):19716. doi:10.2807/ese.15.46.19716-en
77.
Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. The Lancet Infectious Diseases. 2010;10(9):597-602. doi:10.1016/S1473-3099(10)70143-2
78.
Ho PL, Lo WU, Yeung MK, Lin CH, Chow KH, Ang I, et al. Complete sequencing of pNDM-HK encoding NDM-1 carbapenemase from a multidrug-resistant Escherichia coli strain isolated in Hong Kong. PLOS one. 2011;6(3):e17989. doi:10.1371/journal.pone.0017989
79.
Lo JY, Wong TY, Tam CM. An overview of surveillance of antimicrobial resistance by CHP in Hong Kong. Communicable Diseases Watch. 2010;7(17).
80.
Ho PL, Tse CW, Lai EL, Lo WU, Chow KH. Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. International Journal of Antimicrobial Agents. 2011;37(4):386-387. doi:10.1016/j.ijantimicag.2011.01.002
81.
Ghafur A. An obituary–on the death of antibiotics! Journal of the Association of Physicians of India. 2010;58:143-144. https://pubmed.ncbi.nlm.nih.gov/20848810
82.
Ho PL, Li Z, Lai EL, Chiu SS, Cheng VCC. Emergence of NDM-1-producing Enterobacteriaceae in China. Journal of Antimicrobial Chemotherapy. 2012;67(6):1553-1555. doi:10.1093/jac/dks095
83.
Chong S. Cases of New Delhi metallo-β-lactamase (NDM) Carbapenemase-producing Enterobacteriaceae in Hong Kong in 2014. Communicable Diseases Watch. 2015;12(1):3-4. http://www.chp.gov.hk/files/pdf/cdw_compendium_2015.pdf
84.
Ho PL, Cheung YY, Wang Y, Lo WU, Lai EL, Chow KH, et al. Characterization of carbapenem-resistant Escherichia coli and Klebsiella pneumoniae from a healthcare region in Hong Kong. European Journal of Clinical Microbiology & Infectious Diseases. 2016;35(3):379-385. doi:10.1007/s10096-015-2550-3
85.
Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. The Lancet Infectious Diseases. 2016;16(2):161-168. doi:10.1016/S1473-3099(15)00424-7
86.
Wong SCY, Tse H, Chen JHK, Cheng VCC, Ho PL, Yuen KY. Colistin-resistant Enterobacteriaceae carrying the mcr-1 gene among patients in Hong Kong. Emerging Infectious Diseases. 2016;22(9):1667. doi:10.3201/eid2209.160091
87.
Zheng B, Dong H, Xu H, Lv J, Zhang J, Jiang X, et al. Coexistence of MCR-1 and NDM-1 in clinical Escherichia coli isolates. Clinical Infectious Diseases. 2016;63(10):1393-1395. doi:10.1093/cid/ciw553
88.
Yao X, Doi Y, Zeng L, Lv L, Liu JH. Carbapenem-resistant and colistin-resistant Escherichia coli co-producing NDM-9 and MCR-1. The Lancet Infectious Diseases. 2016;16(3):288-289. doi:10.1016/S1473-3099(16)00057-8
89.
Yu H, Qu F, Shan B, Huang B, Jia W, Chen C, et al. Detection of the mcr-1 colistin resistance gene in carbapenem-resistant Enterobacteriaceae from different hospitals in China. Antimicrobial Agents and Chemotherapy. 2016;60(8):5033-5035. doi:10.1128/AAC.00440-16
90.
Delgado-Blas JF, Ovejero CM, Abadia-Patino L, Gonzalez-Zorn B. Coexistence of mcr-1 and blaNDM-1 in Escherichia coli from Venezuela. Antimicrobial Agents and Chemotherapy. 2016;60(10):6356-6358. doi:10.1128/AAC.01319-16
91.
Teo JQ, Ong RT, Xia E, Koh TH, Khor CC, Lee SJ, et al. mcr-1 in multidrug-resistant blaKPC-2-producing clinical Enterobacteriaceae isolates in Singapore. Antimicrobial Agents and Chemotherapy. 2016;60(10):6435-6437. doi:10.1128/AAC.00804-16
92.
Falgenhauer L, Waezsada SE, Yao Y, Imirzalioglu C, Käsbohrer A, Roesler U, et al. Colistin resistance gene mcr-1 in extended-spectrum β-lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany. The Lancet Infectious Diseases. 2016;16(3):282-283. doi:10.1016/S1473-3099(16)00009-8
93.
Fan M, Wong SC, Yu Q, Li PH, Wu P, Chan EWY, et al. Epidemiology and risk factors for carbapenemase-producing Enterobacteriaceae carriage in the hospital: A population-based nested case-control study. Journal of Global Antimicrobial Resistance. 2023;33:242-248. doi:10.1016/j.jgar.2023.03.013
94.
Zhu C, Li C, Lai CKC, Ng R, Chau KY, Wong KT, et al. Longitudinal genomic characterization of carbapenemase-producing Enterobacteriaceae (CPE) reveals changing pattern of CPE Isolated in Hong Kong Hospitals. International Journal of Antimicrobial Agents. 2021;58(5):106430. doi:10.1016/j.ijantimicag.2021.106430
95.
Centre for Food Safety, the Government of the Hong Kong Special Administrative Region. Antimicrobial Resistance and Food Safety. Published online December 2024. Accessed December 20, 2024. https://www.cfs.gov.hk/english/whatsnew/whatsnew_fstr
/AMR_surveillance_findings.html
96.
Centre for Health Protection, Department of Health, the Government of the Hong Kong Special Administrative Region. Antimicrobial Resistance Surveillance in Food – Ready-to-eat food. Published online 2024. Accessed December 20, 2024. https://www.chp.gov.hk/en/static/104187.html
97.
Eliopoulos GM, Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clinical Infectious Diseases. 2008;46(8):1254-1263. doi:10.1086/529198
98.
Angulo FJ, Collignon P, Powers JH, Chiller TM, Aidara-Kane A, Aarestrup FM. World Health Organization ranking of antimicrobials according to their importance in human medicine: a critical step for developing risk management strategies for the use of antimicrobials in food production animals. Clinical Infectious Diseases. 2009;49(1):132-141. doi:10.1086/599374
99.
Ho PL, Ho AY, Chow KH, Lai EL, Ching P, Seto WH. Epidemiology and clonality of multidrug-resistant Acinetobacter baumannii from a healthcare region in Hong Kong. Journal of Hospital Infection. 2010;74(4):358-364. doi:10.1016/j.jhin.2009.10.015
100.
Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. Journal of Antimicrobial Chemotherapy. 2007;59(3):525-530. doi:10.1093/jac/dkl499
101.
Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. 2007;51(10):3471-3484. doi:10.1128/AAC.01464-06
102.
Fu Y, Zhou J, Zhou H, Yang Q, Wei Z, Yu Y, et al. Wide dissemination of OXA-23-producing carbapenem-resistant Acinetobacter baumannii clonal complex 22 in multiple cities of China. Journal of Antimicrobial Chemotherapy. 2010;65(4):644-650. doi:10.1093/jac/dkq027
103.
Wang H, Guo P, Sun H, Wang H, Yang Q, Chen M, et al. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. Antimicrobial Agents and Chemotherapy. 2007;51(11):4022-4028. doi:10.1128/AAC.01259-06
104.
Richet HM, Mohammed J, McDonald LC, Jarvis WR. Building communication networks: international network for the study and prevention of emerging antimicrobial resistance. Emerging Infectious Diseases. 2001;7(2):319. doi:10.3201/eid0702.010235
105.
World Health Organization. WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Published online 2024:xii, 56 p. https://www.who.int/publications/i/item/9789240093461
106.
Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clinical Microbiology Reviews. 2008;21(3):538-582. doi:10.1128/CMR.00058-07
107.
Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 Carbapenemase gene of Acinetobacter baumannii1. Emerging Infectious Diseases. 2010;16(1):35-40. doi:10.3201/eid1601.090852
108.
Miriagou V, Cornaglia G, Edelstein M, Galani I, Giske CG, Gniadkowski M, et al. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clinical Microbiology and Infection. 2010;16(2):112-122. doi:10.1111/j.1469-0691.2009.03116.x
109.
Cheng VCC, Chen JH, Poon RW, Lee WM, So SY, Wong SC, et al. Control of hospital endemicity of multiple-drug-resistant Acinetobacter baumannii ST457 with directly observed hand hygiene. European Journal of Clinical Microbiology & Infectious Diseases. 2015;34:713-718. doi:10.1007/s10096-014-2281-x
110.
Cheng VCC, Chen JH, So SY, Wong SC, Yan MK, Chau PH, et al. Use of fluoroquinolones is the single most important risk factor for the high bacterial load in patients with nasal and gastrointestinal colonization by multidrug-resistant Acinetobacter baumannii. European Journal of Clinical Microbiology & Infectious Diseases. 2015;34:2359-2366. doi:10.1007/s10096-015-2489-4
111.
Lui L, Wong LC, Chen H, Yung RWH, et al. Antibiogram data from private hospitals in Hong Kong: 6-year retrospective study. Hong Kong Medical Journal. 2022;28(2):140. doi:10.12809/hkmj219806
112.
Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clinical Microbiology Reviews. 2017;30(3):747-809. doi:10.1128/CMR.00114-16
113.
Ho PL, Law PY, Chan BWK, Wong CW, To KKW, Chiu SS, et al. Emergence of Macrolide-Resistant Mycoplasma pneumoniae in Hong Kong Is Linked to Increasing Macrolide Resistance in Multilocus Variable-Number Tandem-Repeat Analysis Type 4-5-7-2. Journal of Clinical Microbiology. 2015;53(11):3560-3564. doi:10.1128/JCM.01983-15
114.
Okazaki N, Narita M, Yamada S, Izumikawa K, Umetsu M, Kenri T, et al. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiology and Immunology. 2001;45(8):617-620. doi:10.1111/j.1348-0421.2001.tb01293.x
115.
Xin D, Mi Z, Han X, Qin L, Li J, Wei T, et al. Molecular mechanisms of macrolide resistance in clinical isolates of mycoplasma pneumoniae from China. Antimicrobial Agents and Chemotherapy. 2009;53(5):2158-2159. doi:10.1128/AAC.01563-08
116.
Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrobial Agents and Chemotherapy. 2009;53(5):2160-2162. doi:10.1128/AAC.01684-08
117.
Cao B, Zhao CJ, Yin YD, Zhao F, Song SF, Bai L, et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clinical Infectious Diseases. 2010;51(2):189-194. doi:10.1086/653535
118.
Zhao F, Liu G, Wu J, Cao B, Tao X, He L, et al. Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrobial Agents and Chemotherapy. 2013;57(3):1521-1523. doi:10.1128/AAC.02060-12
119.
Wu PS, Chang LY, Lin HC, Chi H, Hsieh YC, Huang YC, et al. Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Taiwan. Pediatric pulmonology. 2013;48(9):904-911. doi:10.1002/ppul.22706
120.
Yoo SJ, Kim HB, Choi SH, Lee SO, Kim SH, Hong SB, et al. Differences in the frequency of 23S rRNA gene mutations in Mycoplasma pneumoniae between children and adults with community-acquired pneumonia: clinical impact of mutations conferring macrolide resistance. Antimicrobial Agents and Chemotherapy. 2012;56(12):6393-6396. doi:10.1128/AAC.01421-12
121.
Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. The Pediatric Infectious Disease Journal. 2009;28(8):693-696. doi:10.1097/INF.0b013e31819e3f7a
122.
Ferguson GD, Gadsby NJ, Henderson SS, Hardie A, Kalima P, Morris AC, et al. Clinical outcomes and macrolide resistance in Mycoplasma pneumoniae infection in Scotland, UK. Journal of Medical Microbiology. 2013;62(12):1876-1882. doi:10.1099/jmm.0.066191-0
123.
Caballero J de D, Campo R del, Mafé MDC, Gálvez M, Rodríguez-Domínguez M, Cantón R, et al. First report of macrolide resistance in a Mycoplasma pneumoniae isolate causing community-acquired pneumonia in Spain. Antimicrobial Agents and Chemotherapy. 2014;58(2):1265-1266. doi:10.1128/AAC.02325-13
124.
Dumke R, Baum H von, Lueck PC, Jacobs E. Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany. Clinical Microbiology and Infection. 2010;16(6):613-616. doi:10.1111/j.1469-0691.2009.02968.x
125.
To KK, Chan KH, Fung YF, Yuen KY, Ho PL. Azithromycin treatment failure in macrolide-resistant Mycoplasma pneumoniae pneumonia. European Respiratory Journal. 2010;36(4):969-971. doi:10.1183/09031936.00041910
126.
Lung DC, Chan YH, Kwong L, Que TL. Severe community-acquired pneumonia caused by macrolide-resistant Mycoplasma pneumoniae in a 6-year-old boy. Hong Kong Medical Journal. 2011;17(5):407-409. https://www.hkmj.org/abstracts/v17n5/407.htm
127.
Chan KH, To KK, Chan BW, Li CP, Chiu SS, Yuen KY, et al. Comparison of pyrosequencing, sanger sequencing, and melting curve analysis for detection of low-frequency macrolide-resistant Mycoplasma pneumoniae quasispecies in respiratory specimens. Journal of Clinical Microbiology. 2013;51(8):2592-2598. doi:10.1128/JCM.00785-13
128.
Lung DC, Yip EK, Lam DS, Que TL. Rapid defervescence after doxycycline treatment of macrolide-resistant Mycoplasma pneumoniae-associated community-acquired pneumonia in children. The Pediatric Infectious Disease Journal. 2013;32(12):1396-1399. doi:10.1097/INF.0b013e3182a25c71
129.
Xing FF, Chiu KHY, Deng CW, Ye HY, Sun LL, Su YX, et al. Post-COVID-19 pandemic rebound of macrolide-resistant Mycoplasma pneumoniae infection: A descriptive study. Antibiotics. 2024;13(3):262. doi:10.3390/antibiotics13030262
130.
Norris AH, Shrestha NK, Allison GM, Keller SC, Bhavan KP, Zurlo JJ, et al. 2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy. Clinical Infectious Diseases. 2019;68(1):e1-e35. doi:10.1093/cid/ciy745
131.
Muldoon EG, Snydman DR, Penland EC, Allison GM. Are we ready for an outpatient parenteral antimicrobial therapy bundle? A critical appraisal of the evidence. Clinical Infectious Diseases. 2013;57(3):419-424. doi:10.1093/cid/cit211
132.
Tice AD, Rehm SJ, Dalovisio JR, Bradley JS, Martinelli LP, Graham DR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. Clinical Infectious Diseases. 2004;38(12):1651-1671. doi:10.1086/420939
133.
Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clinical Infectious Diseases. 2021;73(5):e1029-e1044. doi:10.1093/cid/ciab549
134.
Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clinical Infectious Diseases. 2020;71(6):1361-1364. doi:10.1093/cid/ciaa303
135.
Gilbert DN, Chambers HF, Saag MS, Pavia A, Boucher HW. The Sanford Guide to Antimicrobial Therapy 2024. Antimicrobial Therapy, Incorporated; 2024. https://www.sanfordguide.com/print-guides
/antimicrobial-therapy-library-edition-7-25-x-11 ISBN: 978-1-944272-28-9
136.
Rybak MJ, Lomaestro BM, Rotscahfer JC, Moellering Jr RC, Craig WA, Billeter M, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clinical Infectious Diseases. 2009;49(3):325-327. doi:10.1086/600877
137.
Sivagnanam S, Deleu D. Red man syndrome. Critical Care. 2002;7:1-3. doi:10.1186/cc1871
138.
Alvarez-Arango S, Ogunwole SM, Sequist TD, Burk CM, Blumenthal KG. Vancomycin infusion reaction—moving beyond “red man syndrome”. The New England Journal of Medicine. 2021;384(14):1283. doi:10.1056/NEJMp2031891
139.
Stanford Health Care. Pharmacy Department Policies and Procedures - SHC Vancomycin Dosing Guide. Published online 2023. https://med.stanford.edu/content/dam/sm/bugsanddrugs/documents
/antimicrobial-dosing-protocols/SHC%20Vancomycin%20Dosing%20Guide.pdf
140.
Liu HX, Tang BH, van den Anker J, Hao GX, Zhao W, Zheng Y. Population pharmacokinetics of antibacterial agents in the older population: a literature review. Expert review of Clinical Pharmacology. 2024;17(1):19-31. doi:10.1080/17512433.2023.2295009
141.
Hal SJ van, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrobial Agents and Chemotherapy. 2013;57(2):734-744. doi:10.1128/aac.01568-12
142.
Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrobial Agents and Chemotherapy. 2014;58(1):309-316. doi:10.1128/AAC.01653-13
143.
Tongsai S, Koomanachai P. The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis. BMC Research Notes. 2016;9(1):455. doi:10.1186/s13104-016-2252-7
144.
Hammoud K, Brimacombe M, Yu A, Goodloe N, Haidar W, El Atrouni W. Vancomycin Trough and Acute Kidney Injury: A Large Retrospective, Cohort Study. American Journal of Nephrology. 2016;44(6):456-461. doi:10.1159/000452427
145.
Filippone EJ, Kraft WK, Farber JL. The Nephrotoxicity of Vancomycin. Clinical Pharmacology and Therapeutics. 2017;102(3):459-469. doi:10.1002/cpt.726
146.
He N, Su S, Ye Z, Du G, He B, Li D, et al. Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring, Chinese pharmacological society. Clinical Infectious Diseases. 2020;71(Supplement_4):S363-S371. doi:10.1093/cid/ciaa1536
147.
Stewart JJ, Jorgensen SC, Dresser L, Lau TT, Gin A, Thirion DJ, et al. A Canadian perspective on the revised 2020 ASHP-IDSA-PIDS-SIDP guidelines for vancomycin AUC-based therapeutic drug monitoring for serious MRSA infections. Journal of the Association of Medical Microbiology and Infectious Disease Canada. 2021;6(1):3-9. doi:10.3138/jammi-2020-0028
148.
Matsumoto K, Samura M, Tashiro S, Shishido S, Saiki R, Takemura W, et al. Target Therapeutic Ranges of Anti-MRSA Drugs, Linezolid, Tedizolid and Daptomycin, and the Necessity of TDM. Biological & Pharmaceutical Bulletin. 2022;45(7):824-833. doi:10.1248/bpb.b22-00276
149.
Minter DJ, Appa A, Chambers HF, Doernberg SB. Contemporary management of Staphylococcus aureus bacteremia—controversies in clinical practice. Clinical Infectious Diseases. 2023;77(11):e57-e68. doi:10.1093/cid/ciad500
150.
Bellos I, Daskalakis G, Pergialiotis V. Relationship of vancomycin trough levels with acute kidney injury risk: an exposure–toxicity meta-analysis. Journal of Antimicrobial Chemotherapy. 2020;75(10):2725-2734. doi:10.1093/jac/dkaa184
151.
Dilworth TJ, Schulz LT, Rose WE. Vancomycin advanced therapeutic drug monitoring: exercise in futility or virtuous endeavor to improve drug efficacy and safety? Clinical Infectious Diseases. 2021;72(10):e675-e681. doi:10.1093/cid/ciaa1354
152.
Jorgensen SCJ, Spellberg B, Shorr AF, Wright WF. Should Therapeutic Drug Monitoring Based on the Vancomycin Area Under the Concentration-Time Curve Be Standard for Serious Methicillin-Resistant Staphylococcus aureus Infections?—No. Clinical Infectious Diseases. 2021;72(9):1502-1506. doi:10.1093/cid/ciaa1743
153.
Lodise TP, Drusano G. Vancomycin area under the curve–guided dosing and monitoring for adult and pediatric patients with suspected or documented serious methicillin-resistant Staphylococcus aureus infections: putting the safety of our patients first. Clinical Infectious Diseases. 2021;72(9):1497-1501. doi:10.1093/cid/ciaa1744
154.
Wright WF, Jorgensen SC, Spellberg B. Heaping the pelion of vancomycin on the ossa of methicillin-resistant Staphylococcus aureus: back to basics in clinical care and guidelines. Clinical Infectious Diseases. 2021;72(10):e682-e684. doi:10.1093/cid/ciaa1360
155.
Konvinse KC, Trubiano JA, Pavlos R, James I, Shaffer CM, Bejan CA, et al. HLA-A* 32: 01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. Journal of Allergy and Clinical Immunology. 2019;144(1):183-192. doi:10.1016/j.jaci.2019.01.045
156.
Schwarz S, Zhang W, Du XD, Krüger H, Feßler AT, Ma S, et al. Mobile oxazolidinone resistance genes in Gram-positive and Gram-negative bacteria. Clinical Microbiology Reviews. 2021;34(3):10-1128. doi:10.1128/CMR.00188-20
157.
United States Food and Drug Administration. Highlights of prescribing information – linezolid. Published online June 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024
/021130s046,021131s044,021132s046lbl.pdf
158.
Matsumoto K, Takeda Y, Takeshita A, Fukunaga N, Shigemi A, Yaji K, et al. Renal function as a predictor of linezolid-induced thrombocytopenia. International Journal of Antimicrobial Agents. 2009;33(1):98-99. doi:10.1016/j.ijantimicag.2008.07.002
159.
Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. Journal of Antimicrobial Chemotherapy. 2013;68(9):2128-2133. doi:10.1093/jac/dkt133
160.
Crass RL, Cojutti PG, Pai MP, Pea F. Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety. Antimicrobial Agents and Chemotherapy. 2019;63(8):e00605-19. doi:10.1128/AAC.00605-19
161.
Giunio-Zorkin N, Brown G. Real-Life Frequency of New-Onset Thrombocytopenia during Linezolid Treatment. The Canadian Journal of Hospital Pharmacy. 2019;72(2):133-138. doi:10.4212/cjhp.v72i2.2883
162.
Laarhuis SRE, Kerskes CHM, Nijziel MR, Wensen RJA van, Touw DJ. Linezolid-Induced Thrombocytopenia in Patients with Renal Impairment: A Case Series, Review and Dose Advice. Drugs in R&D. 2024;24(1):109-115. doi:10.1007/s40268-024-00458-6
163.
Sasaki T, Takane H, Ogawa K, Isagawa S, Hirota T, Higuchi S, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrobial Agents and Chemotherapy. 2011;55(5):1867-1873. doi:10.1128/AAC.01185-10
164.
Zhang S, Zhu Z, Chen Z, Li Y, Zou Y, Yan M, et al. Population Pharmacokinetics and Dosage Optimization of Linezolid in Patients with Liver Dysfunction. Antimicrobial Agents and Chemotherapy. 2020;64(6):e00133-20. doi:10.1128/AAC.00133-20
165.
Wu VC, Wang YT, Wang CY, Tsai IJ, Wu KD, Hwang JJ, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clinical Infectious Diseases. Published online 2006:66-72. doi:10.1086/498509
166.
Mao Y, Dai D, Jin H, Wang Y. The risk factors of linezolid-induced lactic acidosis: A case report and review. Medicine. 2018;97(36):e12114. doi:10.1097/MD.0000000000012114
167.
Swaminathan A, du Cros P, Seddon JA, Mirgayosieva S, Asladdin R, Dusmatova Z. Peripheral neuropathy in a diabetic child treated with linezolid for multidrug-resistant tuberculosis: a case report and review of the literature. BMC Infectious Diseases. 2017;17:1-5. doi:10.1186/s12879-017-2499-1
168.
Miller HV, Cao AA, McClelland CM, Lee MS. Linezolid optic neuropathy. Current Opinion in Ophthalmology. 2023;34(6):481-486. doi:10.1097/ICU.0000000000000995
169.
Butterfield JM, Lawrence KR, Reisman A, Huang DB, Thompson CA, Lodise TP. Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of Phase III and IV randomized clinical trial data. Journal of Antimicrobial Chemotherapy. 2012;67(2):494-502. doi:10.1093/jac/dkr467
170.
Elbarbry F, Moshirian N. Linezolid-associated serotonin toxicity: a systematic review. European Journal of Clinical Pharmacology. 2023;79(7):875-883. doi:10.1007/s00228-023-03500-9
171.
Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clinical Infectious Diseases. 2006;42(11):1578-1583. doi:10.1086/503839
172.
Viswanathan P, Iarikov D, Wassel R, Davidson A, Nambiar S. Hypoglycemia in patients treated with linezolid. Clinical Infectious Diseases. 2014;59(8):e93-e95. doi:10.1093/cid/ciu487
173.
Dong QW, Tang L, Ge DD, Zhou TY, Zhao YC, Ma CH, et al. A case of linezolid-induced SIADH in elderly and a review of the literature. European Review for Medical and Pharmacological Sciences. 2022;26(16):5706-5709. doi:10.26355/eurrev_202208_29505
174.
Satlin MJ, Nicolau DP, Humphries RM, Kuti JL, Campeau SA, Lewis II JS, et al. Development of daptomycin susceptibility breakpoints for Enterococcus faecium and revision of the breakpoints for other enterococcal species by the Clinical and Laboratory Standards Institute. Clinical Infectious Diseases. 2020;70(6):1240-1246. doi:10.1093/cid/ciz845
175.
Turnidge J, Kahlmeter G, Cantón R, MacGowan A, Giske CG, European Committee on Antimicrobial Susceptibility Testing, et al. Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper. Clinical Microbiology and Infection. 2020;26(8):1039-1043. doi:10.1016/j.cmi.2020.04.027
176.
Brown NM, Goodman AL, Horner C, Jenkins A, Brown EM. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. JAC-Antimicrobial Resistance. 2021;3(1):dlaa114. doi:10.1093/jacamr/dlaa114
177.
Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. The New England Journal of Medicine. 2006;355(7):653-665. doi:10.1056/NEJMoa053783
178.
Britt NS, Potter EM, Patel N, Steed ME. Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among Veterans Affairs patients. Clinical Infectious Diseases. 2017;64(5):605-613. doi:10.1093/cid/ciw815
179.
Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, et al. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrobial Agents and Chemotherapy. 2013;57(9):4190-4196. doi:10.1128/AAC.00526-13
180.
Chuang YC, Lin HY, Yang JL, Lin CY, Huang SH, Wang JT, et al. Influence of daptomycin doses on the outcomes of VRE bloodstream infection treated with high-dose daptomycin. Journal of Antimicrobial Chemotherapy. 2022;77(8):2278-2287. doi:10.1093/jac/dkac164
181.
Bassetti M, Nicco E, Ginocchio F, Ansaldi F, Florentiis D de, Viscoli C. High-dose daptomycin in documented Staphylococcus aureus infections. International Journal of Antimicrobial Agents. 2010;36(5):459-461. doi:10.1016/j.ijantimicag.2010.07.011
182.
Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2011;31(6):527-536. doi:10.1592/phco.31.6.527
183.
Carugati M, Bayer AS, Miró JM, Park LP, Guimarães AC, Skoutelis A, et al. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis. Antimicrobial Agents and Chemotherapy. 2013;57(12):6213-6222. doi:10.1128/AAC.01563-13
184.
Gould IM, Miró JM, Rybak MJ. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. International Journal of Antimicrobial Agents. 2013;42(3):202-210. doi:10.1016/j.ijantimicag.2013.05.005
185.
Kullar R, Casapao AM, Davis SL, Levine DP, Zhao JJ, Crank CW, et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. Journal of Antimicrobial Chemotherapy. 2013;68(12):2921-2926. doi:10.1093/jac/dkt294
186.
Malizos K, Sarma J, Seaton RA, Militz M, Menichetti F, Riccio G, et al. Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry. European Journal of Clinical Microbiology & Infectious Diseases. 2016;35(1):111-118. doi:10.1007/s10096-015-2515-6
187.
Jones TW, Jun AH, Michal JL, Olney WJ. High-dose daptomycin and clinical applications. Annals of Pharmacotherapy. 2021;55(11):1363-1378. doi:10.1177/1060028021991943
189.
Chuma M, Nakamoto A, Bando T, Niimura T, Kondo Y, Hamano H, et al. Association between statin use and daptomycin-related musculoskeletal adverse events: a mixed approach combining a meta-analysis and a disproportionality analysis. Clinical Infectious Diseases. 2022;75(8):1416-1422. doi:10.1093/cid/ciac128
190.
Bartal C, Sagy I, Barski L. Drug-induced eosinophilic pneumonia: A review of 196 case reports. Medicine. 2018;97(4):e9688. doi:10.1097/MD.0000000000009688
191.
Grégoire C, Brumpt C, Loirat D, Lau N, Bruel C, Philippart F, et al. A Case of Daptomycin-Induced Immune Thrombocytopenia. Antimicrobial Agents and Chemotherapy. 2012;56(12):6430-6431. doi:10.1128/AAC.01787-12
192.
Olson MW, Ruzin A, Feyfant E, Rush III TS, O’Connell J, Bradford PA. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrobial Agents and Chemotherapy. 2006;50(6):2156-2166. doi:10.1128/AAC.01499-05
193.
Stein GE, Craig WA. Tigecycline: A Critical Analysis. Clinical Infectious Diseases. 2006;43(4):518-524. doi:10.1086/505494
194.
Yaghoubi S, Zekiy AO, Krutova M, Gholami M, Kouhsari E, Sholeh M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. European Journal of Clinical Microbiology & Infectious Diseases. 2022;41(7):1003-1022. doi:10.1007/s10096-020-04121-1
195.
United States Food and Drug Administration. FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. Published online January 2010. https://www.fda.gov/drugs/drug-safety-and-availability
/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics
196.
Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clinical Infectious Diseases. 2012;54(12):1699-1709. doi:10.1093/cid/cis270
197.
Powers JH. Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what’s important in unbiased evaluations of antimicrobials. Clinical Infectious Diseases. 2012;54(12):1710-1713. doi:10.1093/cid/cis274
198.
United States Food and Drug Administration. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. Published online September 2013. Accessed December 20, 2024. https://www.fda.gov/drugs/drug-safety-and-availability
/fda-drug-safety-communication-fda-warns-increased-risk-death-iv-antibacterial-tygacil-tigecycline
199.
United States Food and Drug Administration. Highlights of prescribing information – tigecycline injection. Published online May 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211158s006lbl.pdf
200.
Gilson M, Moachon L, Jeanne L, Dumaine V, Eyrolle L, Morand P, et al. Acute pancreatitis related to tigecycline: case report and review of the literature. Scandinavian journal of infectious diseases. 2008;40(8):681-683. doi:10.1080/00365540801938949
201.
Lipshitz J, Kruh J, Cheung P, Cassagnol M. Tigecycline-induced pancreatitis. Journal of Clinical Gastroenterology. 2009;43(1):93. doi:10.1097/MCG.0b013e318164939c
202.
Lin J, Wang R, Chen J. Tigecycline-induced acute pancreatitis in a renal transplant patient: a case report and literature review. BMC Infectious Diseases. 2018;18:1-6. doi:10.1186/s12879-018-3103-z
203.
Wang P, Zou H, Zhu J, Shi F. Acute pancreatitis caused by tigecycline: a case report and literature review. Medicine. 2021;100(51):e28245. doi:10.1097/MD.0000000000028245
204.
Pieringer H, Schmekal B, Biesenbach G, Pohanka E. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. Annals of Hematology. 2010;89(10):1063-1064. doi:10.1007/s00277-010-0911-7
205.
Rossitto G, Piano S, Rosi S, Simioni P, Angeli P. Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis. European Journal of Gastroenterology & Hepatology. 2014;26(6):681-684. doi:10.1097/MEG.0000000000000087
206.
Sabanis N, Paschou E, Gavriilaki E, Kalaitzoglou A, Vasileiou S. Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder. Infectious Diseases. 2015;47(10):743-746. doi:10.3109/23744235.2015.1043942
207.
Fan Q, Huang W, Weng Y, Xie X, Shi Z. Hypofibrinogenemia induced by high-dose tigecycline—case report and review of literature. Medicine. 2020;99(43):e22638. doi:10.1097/MD.0000000000022638
208.
Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clinical Infectious Diseases. 2005;40(9):1333-1341. doi:10.1086/429323
209.
Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski III A, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2010;30(12):1279-1291. doi:10.1592/phco.30.12.1279
210.
Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), Infectious Diseases Society of America (IDSA), international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP). Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2019;39(1):10-39. doi:10.1002/phar.2209
211.
Ling Z, Yin W, Shen Z, Wang Y, Shen J, Walsh TR. Epidemiology of mobile colistin resistance genes mcr-1 to mcr-9. Journal of Antimicrobial Chemotherapy. 2020;75(11):3087-3095. doi:10.1093/jac/dkaa205
212.
Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clinical Infectious Diseases. 2013;57(4):524-531. doi:10.1093/cid/cit334
213.
Wang P, Zhang Q, Feng M, Sun T, Yang J, Zhang X. Population pharmacokinetics of polymyxin B in obese patients for resistant Gram-negative infections. Frontiers in Pharmacology. 2021;12:754844. doi:10.3389/fphar.2021.754844
214.
Kassamali Z, Jain R, Danziger LH. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics. International Journal of Infectious Diseases. 2015;30:125-132. doi:10.1016/j.ijid.2014.10.014
215.
Meng L, Mui E, Ha DR, Stave C, Deresinski SC, Holubar M. Comprehensive guidance for antibiotic dosing in obese adults: 2022 update. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023;43(3):226-246. doi:10.1002/phar.2769
216.
Kwa ALH, Abdelraouf K, Low JGH, Tam VH. Pharmacokinetics of Polymyxin B in a Patient With Renal Insufficiency: A Case Report. Clinical Infectious Diseases. 2011;52(10):1280-1281. doi:10.1093/cid/cir137
217.
Thamlikitkul V, Dubrovskaya Y, Manchandani P, Ngamprasertchai T, Boonyasiri A, Babic JT, et al. Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency. Antimicrobial Agents and Chemotherapy. 2017;61(1):e01337-16. doi:10.1128/AAC.01337-16
218.
Zavascki AP, Nation RL. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B? Antimicrobial Agents and Chemotherapy. 2017;61(3):e02319-16. doi:10.1128/AAC.02319-16
219.
Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. Journal of Antimicrobial Chemotherapy. 2010;65(10):2231-2237. doi:10.1093/jac/dkq285
220.
Nelson BC, Eiras DP, Gomez-Simmonds A, Loo AS, Satlin MJ, Jenkins SG, et al. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. Antimicrobial Agents and Chemotherapy. 2015;59(11):7000-7006. doi:10.1128/AAC.00844-15
221.
Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Critical Care. 2006;10:1-13. doi:10.1186/cc3995
222.
Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Review of Anti-infective Therapy. 2007;5(5):811-821. doi:10.1586/14787210.5.5.811
223.
Wunsch H, Moitra VK, Patel M, Dzierba AL. Polymyxin Use Associated With Respiratory Arrest. Chest. 2012;141(2):515-517. doi:10.1378/chest.11-1483
224.
Mattos KPH, Cintra ML, Gouvêa IR, Ferreira LÁ, Velho PENF, Moriel P. Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process. Journal of Clinical Pharmacy and Therapeutics. 2017;42(5):573-578. doi:10.1111/jcpt.12543
225.
Gauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L, Smith LB. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrobial Agents and Chemotherapy. 2012;56(5):2392-2396. doi:10.1128/AAC.00028-12
226.
DeRyke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrobial Agents and Chemotherapy. 2010;54(10):4503-4505. doi:10.1128/AAC.01707-09
227.
Lam SW, Athans V. Clinical and microbiological outcomes in obese patients receiving colistin for carbapenem-resistant gram-negative bloodstream infection. Antimicrobial Agents and Chemotherapy. 2019;63(9):10-1128. doi:10.1128/AAC.00531-19
228.
Haseeb A, Faidah HS, Alghamdi S, Alotaibi AF, Elrggal ME, Mahrous AJ, et al. Dose optimization of colistin: A systematic review. Antibiotics. 2021;10(12):1454. doi:10.3390/antibiotics10121454
229.
Justo JA, Bosso JA. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2015;35(1):28-33. doi:10.1002/phar.1493
231.
Santos C dos, Santos LS dos, Franco OL. Fosfomycin and nitrofurantoin: classic antibiotics and perspectives. The Journal of Antibiotics. 2021;74(9):547-558. doi:10.1038/s41429-021-00444-z
232.
Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clinical Microbiology Reviews. 2016;29(2):321-347. doi:10.1128/CMR.00068-15
233.
Flamm RK, Rhomberg PR, Watters AA, Sweeney K, Ellis-Grosse EJ, Shortridge D. Activity of fosfomycin when tested against US contemporary bacterial isolates. Diagnostic Microbiology and Infectious Disease. 2019;93(2):143-146. doi:10.1016/j.diagmicrobio.2018.08.010
234.
Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical Infectious Diseases. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257
235.
Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, et al. Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial. JAMA. 2018;319(17):1781-1789. doi:10.1001/jama.2018.3627
236.
Gágyor I. Single-dose fosfomycin is less effective than 5-day nitrofurantoin in women with uncomplicated urinary tract infection: closing the evidence gap for a new recommendation of an old antibiotic. BMJ Evidence-Based Medicine. 2019;24(5):e3-e3. doi:10.1136/bmjebm-2018-111063
237.
Kurotschka PK, Gágyor I, Ebell MH. Acute Uncomplicated UTIs in Adults: Rapid Evidence Review. American Family Physician. 2024;109(2):167-174. https://www.aafp.org/pubs/afp/issues/2024/0200
/acute-uncomplicated-utis-adults.html
238.
Apgar B. Single-dose fosfomycin for urinary tract infection. American Family Physician. 1998;57(6):1411-1412. https://www.aafp.org/pubs/afp/issues/1998/0315/p1411.html
239.
Iarikov D, Wassel R, Farley J, Nambiar S. Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database. Infectious Diseases and Therapy. 2015;4(4):433-458. doi:10.1007/s40121-015-0092-8
240.
Biek D, Critchley IA, Riccobene TA, Thye DA. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. Journal of Antimicrobial Chemotherapy. 2010;65 Suppl 4:iv9-16. doi:10.1093/jac/dkq251
241.
Welte T, Kantecki M, Stone GG, Hammond J. Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults. International Journal of Antimicrobial Agents. 2019;54(4):410-422. doi:10.1016/j.ijantimicag.2019.08.012
242.
File TM, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. Journal of Antimicrobial Chemotherapy. 2011;66 Suppl 3:iii19-32. doi:10.1093/jac/dkr096
243.
Low DE, File TM, Eckburg PB, Talbot GH, David Friedland H, Lee J, et al. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. Journal of Antimicrobial Chemotherapy. 2011;66 Suppl 3:iii33-44. doi:10.1093/jac/dkr097
244.
File Jr TM, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clinical Infectious Diseases. 2012;55(Suppl 3):S173-S180. doi:10.1093/cid/cis559
245.
Zhong NS, Sun T, Zhuo C, D’Souza G, Lee SH, Lan NH, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. The Lancet Infectious Diseases. 2015;15(2):161-171. doi:10.1016/S1473-3099(14)71018-7
246.
Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrobial Agents and Chemotherapy. 2014;58(5):2541-2546. doi:10.1128/AAC.02371-13
247.
Destache CJ, Guervil DJ, Kaye KS. Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience. International Journal of Antimicrobial Agents. 2019;53(5):644-649. doi:10.1016/j.ijantimicag.2019.01.014
248.
Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. Journal of Antimicrobial Chemotherapy. 2012;67(5):1267-1270. doi:10.1093/jac/dks006
249.
Kaushik D, Rathi S, Jain A. Ceftaroline: a comprehensive update. International Journal of Antimicrobial Agents. 2011;37(5):389-395. doi:10.1016/j.ijantimicag.2011.01.017
250.
Shirley DAT, Heil EL, Johnson JK. Ceftaroline fosamil: A Brief Clinical Review. Infectious Diseases and Therapy. 2013;2(2):95-110. doi:10.1007/s40121-013-0010-x
251.
Martin TCS, Chow S, Johns ST, Mehta SR. Ceftaroline-associated encephalopathy in patients with severe renal impairment. Clinical Infectious Diseases. 2020;70(9):2002-2004. doi:10.1093/cid/ciz857
252.
Ehmann DE, Jahić H, Ross PL, Gu RF, Hu J, Kern G, et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(29):11663-11668. doi:10.1073/pnas.1205073109
253.
Sternbach N, Leibovici Weissman Y, Avni T, Yahav D. Efficacy and safety of ceftazidime/avibactam: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy. 2018;73(8):2021-2029. doi:10.1093/jac/dky124
254.
Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β-Lactam-β-Lactamase Inhibitor Combinations. Clinical Microbiology Reviews. 2020;34(1). doi:10.1128/cmr.00115-20
255.
Hobson CA, Pierrat G, Tenaillon O, Bonacorsi S, Bercot B, Jaouen E, et al. Klebsiella pneumoniae carbapenemase variants resistant to ceftazidime-avibactam: an evolutionary overview. Antimicrobial Agents and Chemotherapy. 2022;66(9):e00447-22. doi:10.1128/aac.00447-22
256.
Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clinical Infectious Diseases. Published online 2024:ciae403. doi:10.1093/cid/ciae403
257.
Falcone M, Daikos GL, Tiseo G, Bassoulis D, Giordano C, Galfo V, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-β-lactamase–producing Enterobacterales. Clinical Infectious Diseases. 2021;72(11):1871-1878. doi:10.1093/cid/ciaa586
258.
Di Bella S, Giacobbe DR, Maraolo AE, Viaggi V, Luzzati R, Bassetti M, et al. Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies. Journal of Global Antimicrobial Resistance. 2021;25:268-281. doi:10.1016/j.jgar.2021.04.001
259.
Simner PJ, Bergman Y, Conzemius R, Jacobs E, Tekle T, Beisken S, et al. An NDM-Producing Escherichia coli Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-β-Lactam Resistance. Open Forum Infectious Diseases. 2023;10(7):ofad276. doi:10.1093/ofid/ofad276
260.
Lizza BD, Betthauser KD, Ritchie DJ, Micek ST, Kollef MH. New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam. Antimicrobial Agents and Chemotherapy. 2021;65(7):e0231820. doi:10.1128/AAC.02318-20
261.
Bonomo RA. Cefiderocol: a novel siderophore cephalosporin defeating carbapenem-resistant pathogens. Clinical Infectious Diseases. 2019;69(Supplement_7):S519-S520. doi:10.1093/cid/ciz823
262.
McCreary EK, Heil EL, Tamma PD. New Perspectives on Antimicrobial Agents: Cefiderocol. Antimicrobial Agents and Chemotherapy. 2021;65(8):e02171-20. doi:10.1128/AAC.02171-20
263.
Ong’uti S, Czech M, Robilotti E, Holubar M. Cefiderocol: a new cephalosporin stratagem against multidrug-resistant Gram-negative bacteria. Clinical Infectious Diseases. 2022;74(7):1303-1312. doi:10.1093/cid/ciab757
264.
Simner PJ, Patel R. Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles’ Heel of the Trojan Horse? Journal of Clinical Microbiology. 2020;59(1):e00951-20. doi:10.1128/JCM.00951-20
265.
Syed YY. Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections. Drugs. 2021;81(13):1559-1571. doi:10.1007/s40265-021-01580-4
266.
Fouad A, Nicolau DP, Gill CM. In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii, P. aeruginosa and Enterobacterales. Journal of Antimicrobial Chemotherapy. 2023;78(12):2801-2809. doi:10.1093/jac/dkad244
267.
Karlowsky JA, Hackel MA, McLeod SM, Miller AA. In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021. Antimicrobial Agents and Chemotherapy. 2022;66(9):e00781-22. doi:10.1128/aac.00781-22
268.
Seifert H, Müller C, Stefanik D, Higgins PG, Miller A, Kresken M. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy. 2020;75(9):2616-2621. doi:10.1093/jac/dkaa208
269.
Covvey JR, Guarascio AJ. Sulbactam-durlobactam for the treatment of acinetobacter baumannii-calcoaceticus complex. Expert Review of Anti-infective Therapy. 2024;22(11):925-934. doi:10.1080/14787210.2024.2400703
270.
Keam SJ. Sulbactam/Durlobactam: First Approval. Drugs. 2023;83(13):1245-1252. doi:10.1007/s40265-023-01920-6
271.
Tamma PD, Munita JM. The metallo-β-lactamases strike back: emergence of taniborbactam escape variants. Antimicrobial Agents and Chemotherapy. 2024;68(2):e01510-23. doi:10.1128/aac.01510-23
272.
Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, et al. Cefepime-Taniborbactam in Complicated Urinary Tract Infection. The New England Journal of Medicine. 2024;390(7):611-622. doi:10.1056/NEJMoa2304748
273.
Stankowicz MS, Ibrahim J, Brown DL. Once-daily aminoglycoside dosing: an update on current literature. American Journal of Health-System Pharmacy. 2015;72(16):1357-1364. doi:10.2146/ajhp140564
274.
Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ. 2004;328(7441):668. doi:10.1136/bmj.38028.520995.63
275.
Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database of Systematic Reviews. 2014;2018(12). doi:10.1002/14651858.cd003344.pub3
276.
Block M, Blanchard DL. StatPearls. In: StatPearls Publishing; 2024. Accessed December 20, 2024. http://www.ncbi.nlm.nih.gov/books/NBK541105
277.
Queensland Health, Queensland Government. Aminoglycoside Dosing in Adults. Published online May 2018. Accessed December 20, 2024. https://www.health.qld.gov.au/__data/assets/pdf_file/0019/713323
/aminoglycoside-guidelines.pdf
279.
Serio AW, Keepers T, Andrews L, Krause KM. Aminoglycoside revival: review of a historically important class of antimicrobials undergoing rejuvenation. EcoSal Plus. 2018;8(1):10-1128. doi:10.1128/ecosalplus.esp-0002-2018
280.
Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124
281.
Drug Office, Department of Health, the Government of the Hong Kong Special Administrative Region. Other safety alerts - Australia: Update: Fluoroquinolone antibiotics and adverse events. Published online February 2020. Accessed December 20, 2024. https://www.drugoffice.gov.hk/eps/news/showNews/Australia%3A+Update%3A
+fluoroquinolone+antibiotics+and+adverse+events/pharmaceutical_trade
/2020-02-27/en/39569.html
282.
Drug Office, Department of Health, the Government of the Hong Kong Special Administrative Region. Other safety alerts - The United Kingdom: Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects. Published online August 2023. Accessed December 20, 2024. https://www.drugoffice.gov.hk/eps/news/showNews/The+United+Kingdom%3A
+Fluoroquinolone+antibiotics%3A+reminder+of+the+risk+of+disabling+and
+potentially+long-lasting+or+irreversible+side+effects/pharmaceutical_trade
/2023-08-31/en/50871.html
283.
United States Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Published online December 2016. https://www.fda.gov/drugs/drug-safety-and-availability
/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain
284.
European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. Published online November 2018. https://www.ema.europa.eu/en/medicines/human/referrals
/quinolone-fluoroquinolone-containing-medicinal-products
285.
United States Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Published online July 2016. https://www.fda.gov/drugs/drug-safety-and-availability
/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics
286.
Drug Office, Department of Health, the Government of the Hong Kong Special Administrative Region. ADR that result in revision of patient information - the United Kingdom: Fluoroquinolone antibiotics: Must now only be prescribed when other commonly recommended antibiotics are inappropriate. Published online January 2024. Accessed December 20, 2024. https://www.drugoffice.gov.hk/eps/news/showNews/The+United+Kingdom%3A
+Fluoroquinolone+antibiotics%3A+must+now+only+be+prescribed+when+other
+commonly+recommended+antibiotics+are+inappropriate/pharmaceutical_trade
/2024-01-23/en/52609.html
287.
United States Food and Drug Administration. Postmarket Drug Safety Information for Patients and Providers - Information for Healthcare Professionals: Fluoroquinolone Antimicrobial Drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)]. Published online July 2008. https://wayback.archive-it.org/7993/20161022101528/http:/www.fda.gov/Drugs
/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders
/ucm126085.htm
288.
United States Food and Drug Administration. Drug Safety and Availability - FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. Published online August 2023. https://wayback.archive-it.org/7993/20161022101530/http:/www.fda.gov/Drugs
/DrugSafety/ucm365050.htm
289.
Medicines and Healthcare products Regulatory Agency. Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects. Published online March 2019. Accessed December 20, 2024. https://www.gov.uk/drug-safety-update
/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects
290.
Medicines and Healthcare products Regulatory Agency. Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate. Published online January 2024. Accessed December 20, 2024. https://www.gov.uk/drug-safety-update
/fluoroquinolone-antibiotics-must-now-only-be-prescribed-when-other-commonly-recommended-antibiotics-are-inappropriate
291.
Baggio D, Ananda-Rajah MR. Fluoroquinolone antibiotics and adverse events. Australian Prescriber. 2021;44(5):161-164. doi:10.18773/austprescr.2021.035
292.
Medicines and Healthcare products Regulatory Agency. MHRA Issues Further Update on Fluoroquinolone Safety. Drug and Therapeutics Bulletin. 2024;62(6):83. doi:10.1136/dtb.2024.000021
293.
Medicines and Healthcare products Regulatory Agency. Fluoroquinolone antibiotics: suicidal thoughts and behaviour. Published online September 2023. Accessed December 20, 2024. https://www.gov.uk/drug-safety-update
/fluoroquinolone-antibiotics-suicidal-thoughts-and-behaviour
294.
Sodhi M, Sheldon CA, Carleton B, Etminan M. Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: Nested case-control study. Neurology. 2017;89(8):792-795. doi:10.1212/WNL.0000000000004247
295.
Trillenberg P, Thern J. Antibiotic-induced myasthenia worsening-an estimation of risk based on reporting frequency. Journal of Antimicrobial Chemotherapy. 2020;75(11):3408-3410. doi:10.1093/jac/dkaa298
296.
Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360. doi:10.1136/bmj.k678
297.
Gopalakrishnan C, Bykov K, Fischer MA, Connolly JG, Gagne JJ, Fralick M. Association of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection. JAMA Internal Medicine. 2020;180(12):1596-1605. doi:10.1001/jamainternmed.2020.4199
298.
Lapi F, Wilchesky M, Kezouh A, Benisty JI, Ernst P, Suissa S. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clinical Infectious Diseases. 2012;55(11):1457-1465. doi:10.1093/cid/cis664
299.
Rao GA, Mann JR, Shoaibi A, Bennett CL, Nahhas G, Sutton SS, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Annals of Family Medicine. 2014;12(2):121-127. doi:10.1370/afm.1601
301.
Health Service Executive. Macrolide warnings. Published online December 2023. Accessed December 20, 2024. https://www.hse.ie/eng/services/list/2/gp/antibiotic-prescribing
/drug-interactions/macrolide-warning.html
303.
Therapeutic Goods Administration (TGA), Australian Government. Azithromycin and rare risk of cardiovascular death | Therapeutic Goods Administration (TGA). Published online August 2024. Accessed December 20, 2024. https://www.tga.gov.au/news/safety-updates
/azithromycin-and-rare-risk-cardiovascular-death
304.
Drug Office, Department of Health, the Government of the Hong Kong Special Administrative Region. Other safety alerts - Canada: Azithromycin (Zithromax® /Zmax SR®) - Risk of Potentially Fatal Cardiac Arrhythmias. Published online May 2013. Accessed December 20, 2024. https://www.drugoffice.gov.hk/eps/news/showNews/newsTitle/consumer
/2013-05-18/en/19615.html
306.
Vanoverschelde A, Oosterloo BC, Ly NF, Ikram MA, Goedegebure A, Stricker BH, et al. Macrolide-associated ototoxicity: a cross-sectional and longitudinal study to assess the association of macrolide use with tinnitus and hearing loss. Journal of Antimicrobial Chemotherapy. 2021;76(10):2708-2716. doi:10.1093/jac/dkab232
307.
Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. The New England Journal of Medicine. 2012;366(20):1881-1890. doi:10.1056/NEJMoa1003833
308.
Bin Abdulhak AA, Khan AR, Garbati MA, Qazi AH, Erwin P, Kisra S, et al. Azithromycin and Risk of Cardiovascular Death: A Meta-Analytic Review of Observational Studies. American Journal of Therapeutics. 2015;22(5):e122-129. doi:10.1097/MJT.0000000000000138
309.
Cheng YJ, Nie XY, Chen XM, Lin XX, Tang K, Zeng WT, et al. The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk. Journal of the American College of Cardiology. 2015;66(20):2173-2184. doi:10.1016/j.jacc.2015.09.029
310.
Takashima M, Sugita T. Taxonomy of Pathogenic Yeasts Candida, Cryptococcus, Malassezia, and Trichosporon Current Status, Future Perspectives, and Proposal for Transfer of Six Candida Species to the Genus Nakaseomyces. Medical Mycology Journal. 2022;63(4):119-132. doi:10.3314/mmj.22.004
311.
Borman AM, Johnson EM. Changes in fungal taxonomy: mycological rationale and clinical implications. Clinical Microbiology Reviews. 2023;36(4):e00099-22. doi:10.1128/cmr.00099-22
312.
Liu F, Hu ZD, Zhao XM, Zhao WN, Feng ZX, Yurkov A, et al. Phylogenomic analysis of the Candida auris-Candida haemuli clade and related taxa in the Metschnikowiaceae, and proposal of thirteen new genera, fifty-five new combinations and nine new species. Persoonia-Molecular Phylogeny and Evolution of Fungi. 2024;52(22):22-43. doi:10.3767/persoonia.2024.52.02
313.
Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nature Reviews Disease Primers. 2018;4:18026. doi:10.1038/nrdp.2018.26
314.
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2016;62(4):e1-e50. doi:10.1093/cid/civ933
315.
McCarty TP, White CM, Pappas PG. Candidemia and Invasive Candidiasis. Infectious Disease Clinics of North America. 2021;35(2):389-413. doi:10.1016/j.idc.2021.03.007
316.
Patterson TF, Thompson III GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326
317.
Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clinical Microbiology and Infection. 2018;24:e1-e38. doi:10.1016/j.cmi.2018.01.002
318.
Douglas AP, Smibert OC, Bajel A, Halliday CL, Lavee O, McMullan B, et al. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. Internal Medicine Journal. 2021;51 Suppl 7:143-176. doi:10.1111/imj.15591
319.
Husain S, Camargo JF. Invasive Aspergillosis in solid-organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation. 2019;33(9):e13544. doi:10.1111/ctr.13544
320.
Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. Journal of Antimicrobial Chemotherapy. 2000;46(2):171-179. doi:10.1093/jac/46.2.171
321.
Cuenca-Estrella M, Díaz-Guerra TM, Mellado E, Rodríguez-Tudela JL. Flucytosine primary resistance in Candida species and Cryptococcus neoformans. European Journal of Clinical Microbiology & Infectious Diseases. 2001;20(4):276-279. doi:10.1007/pl00011265
322.
Ellis D. Amphotericin B: spectrum and resistance. Journal of Antimicrobial Chemotherapy. 2002;49 Suppl 1:7-10. doi:10.1093/jac/49.suppl_1.7
323.
Pfaller MA, Messer SA, Boyken L, Huynh H, Hollis RJ, Diekema DJ. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrobial Agents and Chemotherapy. 2002;46(11):3518-3521. doi:10.1128/AAC.46.11.3518-3521.2002
324.
Lemes RML, Lyon JP, Moreira LM, Resende MA de. Antifungal susceptibility profile of Trichosporon isolates: correlation between CLSI and etest methodologies. Brazilian Journal of Microbiology. 2010;41:310-315. doi:10.1590/S1517-83822010000200008
325.
Miceli MH, Díaz JA, Lee SA. Emerging opportunistic yeast infections. The Lancet Infectious Diseases. 2011;11(2):142-151. doi:10.1016/S1473-3099(10)70218-8
326.
Hazirolan G, Canton E, Sahin S, Arikan-Akdagli S. Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii. Antimicrobial Agents and Chemotherapy. 2013;57(10):4841-4847. doi:10.1128/AAC.00850-13
327.
Almeida Júnior JN de, Hennequin C. Invasive Trichosporon Infection: a Systematic Review on a Re-emerging Fungal Pathogen. Frontiers in Microbiology. 2016;7:1629. doi:10.3389/fmicb.2016.01629
328.
Dabas Y, Xess I, Kale P. Molecular and antifungal susceptibility study on trichosporonemia and emergence of Trichosporon mycotoxinivorans as a bloodstream pathogen. Medical Mycology. 2017;55(5):518-527. doi:10.1093/mmy/myw100
329.
Chowdhary A, Sharma C, Meis JF. Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLOS pathogens. 2017;13(5):e1006290. doi:10.1371/journal.ppat.1006290
330.
Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. The Lancet Infectious Diseases. 2017;17(12):e383-e392. doi:10.1016/S1473-3099(17)30316-X
331.
Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins worldwide. Clinical Microbiology and Infection. 2019;25(7):792-798. doi:10.1016/j.cmi.2019.03.028
332.
Jacobs SE, Jacobs JL, Dennis EK, Taimur S, Rana M, Patel D, et al. Candida auris pan-drug-resistant to four classes of antifungal agents. Antimicrobial Agents and Chemotherapy. 2022;66(7):e00053-22. doi:10.1128/aac.00053-22
333.
Puumala E, Fallah S, Robbins N, Cowen LE. Advancements and challenges in antifungal therapeutic development. Clinical Microbiology Reviews. 2024;37(1):e0014223. doi:10.1128/cmr.00142-23
334.
Ross JJ, Davidson L. Methicillin-resistant Staphylococcus aureus septic arthritis: an emerging clinical syndrome. Rheumatology. 2005;44(9):1197-1198. doi:10.1093/rheumatology/kei035
335.
Sharff KA, Richards EP, Townes JM. Clinical management of septic arthritis. Current Rheumatology Reports. 2013;15(6):332. doi:10.1007/s11926-013-0332-4
336.
Lin WT, Wu CD, Cheng SC, Chiu CC, Tseng CC, Chan HT, et al. High prevalence of methicillin-resistant Staphylococcus aureus among patients with septic arthritis caused by Staphylococcus aureus. PLOS one. 2015;10(5):e0127150. doi:10.1371/journal.pone.0127150
337.
McBride S, Mowbray J, Caughey W, Wong E, Luey C, Siddiqui A, et al. Epidemiology, management, and outcomes of large and small native joint septic arthritis in adults. Clinical Infectious Diseases. 2020;70(2):271-279. doi:10.1093/cid/ciz265
338.
Gobao VC, Alfishawy M, Smith C, Byers KE, Yassin M, Urish KL, et al. Risk factors, screening, and treatment challenges in Staphylococcus aureus native septic arthritis. Open Forum Infectious Diseases. 2021;8(1):ofaa593. doi:10.1093/ofid/ofaa593
339.
Wong HK, Yau SK. A local outbreak of invasive infection of Group B Streptococcus ST283 related to freshwater fish, September – October 2024. Communicable Diseases Watch. 2024;20(10):56-58. https://www.chp.gov.hk/files/pdf/cdw_v20_10.pdf
340.
Wong HK. A cluster of invasive Group B Streptococcus ST283 cases. Communicable Diseases Watch. 2023;19(10):57-58. https://www.chp.gov.hk/files/pdf/cdw_v19_10.pdf
341.
Epstein L, Mu Y, Belflower R, Scott J, Ray S, Dumyati G, et al. Risk factors for invasive methicillin-resistant Staphylococcus aureus infection after recent discharge from an acute-care hospitalization, 2011–2013. Clinical Infectious Diseases. 2016;62(1):45-52. doi:10.1093/cid/civ777
342.
Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, et al. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clinical Infectious Diseases. 2015;61(6):e26-e46. doi:10.1093/cid/civ482
343.
Tang CYK, Ho PL. Predictive Factors of Cloxacillin Susceptibility in Primary Bacterial Spinal Infection. Global Spine Journal. Published online 2024:21925682241251814. doi:10.1177/21925682241251814
344.
Pratama V, Risni HW, Yunir E, Sauriasari R. A Systematic Review of Randomized Controlled Trials of Antibiotic Use in Diabetic Foot Ulcer Infections: Focus on Clinical Cure. Infection & Chemotherapy. 2022;54(1):125-139. doi:10.3947/ic.2021.0144
345.
Schaper NC, Dryden M, Kujath P, Nathwani D, Arvis P, Reimnitz P, et al. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Infection. 2013;41(1):175-186. doi:10.1007/s15010-012-0367-x
346.
Xu ZR, Ran XW, Xian Y, Yan XD, Yuan GY, Mu SM, et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial. Journal of Antimicrobial Chemotherapy. 2016;71(6):1688-1696. doi:10.1093/jac/dkw004
347.
Cortes-Penfield NW, Armstrong DG, Brennan MB, Fayfman M, Ryder JH, Tan TW, et al. Evaluation and management of diabetes-related foot infections. Clinical Infectious Diseases. 2023;77(3):e1-e13. doi:10.1093/cid/ciad255
348.
Senneville É, Albalawi Z, Asten SA van, Abbas ZG, Allison G, Aragón-Sánchez J, et al. IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections (IWGDF/IDSA 2023). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3687. doi:10.1002/dmrr.3687
349.
Olid AS, Solà I, Barajas-Nava LA, Gianneo OD, Cosp XB, Lipsky BA. Systemic antibiotics for treating diabetic foot infections. Cochrane Database of Systematic Reviews. 2015;2015(9). doi:10.1002/14651858.cd009061.pub2
350.
Macdonald KE, Boeckh S, Stacey HJ, Jones JD. The microbiology of diabetic foot infections: a meta-analysis. BMC Infectious Diseases. 2021;21:1-10. doi:10.1186/s12879-021-06516-7
351.
Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW. Probing to bone in infected pedal ulcers: a clinical sign of underlying osteomyelitis in diabetic patients. JAMA. 1995;273(9):721-723. doi:10.1001/jama.1995.03520330051036
352.
Morales Lozano R, González Fernández ML, Martinez Hernández D, Beneit Montesinos JV, Guisado Jiménez S, Gonzalez Jurado MA. Validating the probe-to-bone test and other tests for diagnosing chronic osteomyelitis in the diabetic foot. Diabetes Care. 2010;33(10):2140-2145. doi:10.2337/dc09-2309
353.
Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444
354.
Sartelli M, Guirao X, Hardcastle TC, Kluger Y, Boermeester MarjaA, Raşa K, et al. 2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. World Journal of Emergency Surgery. 2018;13:1-24. doi:10.1186/s13017-018-0219-9
356.
Davies MR, Holden MT, Coupland P, Chen JHK, Venturini C, Barnett TC, et al. Emergence of scarlet fever Streptococcus pyogenes emm12 clones in Hong Kong is associated with toxin acquisition and multidrug resistance. Nature Genetics. 2015;47(1):84-87. doi:10.1038/ng.3147
357.
Tang WM, Ho PL, Fung KK, Yuen KY, Leong JCY. Necrotising fasciitis of a limb. The Journal of Bone & Joint Surgery British Volume. 2001;83-B(5):709-714. doi:10.1302/0301-620X.83B5.0830709
358.
Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. The Lancet Infectious Diseases. 2009;9(5):281-290. doi:10.1016/S1473-3099(09)70066-0
360.
Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surgical Infections. 2010;11(1):79-109. doi:10.1086/649554
361.
Linnér A, Darenberg J, Sjölin J, Henriques-Normark B, Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clinical Infectious Diseases. 2014;59(6):851-857. doi:10.1093/cid/ciu449
362.
Parks T, Wilson C, Curtis N, Norrby-Teglund A, Sriskandan S. Polyspecific intravenous immunoglobulin in clindamycin-treated patients with streptococcal toxic shock syndrome: a systematic review and meta-analysis. Clinical Infectious Diseases. 2018;67(9):1434-1436. doi:10.1093/cid/ciy401
363.
Bruun T, Rath E, Madsen MB, Oppegaard O, Nekludov M, Arnell P, et al. Risk factors and predictors of mortality in streptococcal necrotizing soft-tissue infections: a multicenter prospective study. Clinical Infectious Diseases. 2021;72(2):293-300. doi:10.1093/cid/ciaa027
364.
Carapetis JR, Jacoby P, Carville K, Ang SJJ, Curtis N, Andrews R. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clinical Infectious Diseases. 2014;59(3):358-365. doi:10.1093/cid/ciu304
365.
Minami M, Kamimura T, Isaka M, Tatsuno I, Ohta M, Hasegawa T. Clindamycin-induced covS-mediated regulation of the production of virulent exoproteins streptolysin O, NAD glycohydrolase, and streptokinase in Streptococcus pyogenes. Antimicrobial Agents and Chemotherapy. 2010;54(1):98-102. doi:10.1128/AAC.00804-09
366.
Andreoni F, Zürcher C, Tarnutzer A, Schilcher K, Neff A, Keller N, et al. Clindamycin affects group A Streptococcus virulence factors and improves clinical outcome. The Journal of Infectious Diseases. 2017;215(2):269-277. doi:10.1093/infdis/jiw229
367.
Tanaka M, Hasegawa T, Okamoto A, Torii K, Ohta M. Effect of antibiotics on group A Streptococcus exoprotein production analyzed by two-dimensional gel electrophoresis. Antimicrobial Agents and Chemotherapy. 2005;49(1):88-96. doi:10.1128/AAC.49.1.88-96.2005
368.
Fleisher GR. The management of bite wounds. The New England Journal of Medicine. 1999;340(2):138-140. doi:10.1056/NEJM199901143400210
369.
Ellis R, Ellis C. Dog and cat bites. American Family Physician. 2014;90(4):239-243. https://www.aafp.org/pubs/afp/issues/2014/0815/p239.html
370.
Dendle C, Looke D. Review article: Animal bites: an update for management with a focus on infections. Emergency Medicine Australasia. 2008;20(6):458-467. doi:10.1111/j.1742-6723.2008.01130.x
371.
Copsey-Mawer S, Hughes H, Scotford S, Anderson B, Davis C, Perry MD, et al. UK Bacteroides species surveillance survey: Change in antimicrobial resistance over 16 years (2000-2016). Anaerobe. 2021;72:102447. doi:10.1016/j.anaerobe.2021.102447
372.
Fang H, Li X, Yan MK, Tong MK, Chow KH, Cheng VCC, et al. Antimicrobial susceptibility of Bacteroides fragilis group organisms in Hong Kong, 2020-2021. Anaerobe. 2023;82:102756. doi:10.1016/j.anaerobe.2023.102756
373.
Brouwer MC, Coutinho JM, Beek D van de. Clinical characteristics and outcome of brain abscess: systematic review and meta-analysis. Neurology. 2014;82(9):806-813. doi:10.1212/WNL.0000000000000172
374.
Brouwer MC, van de Beek D. Critical Care Neurology Part I. In: Wijdicks EFM, Kramer AH, eds. Vol 140. Handbook of clinical neurology. Elsevier; 2017:349-364. doi:https://doi.org/10.1016/B978-0-444-63600-3.00019-2
375.
Bodilsen J, D’Alessandris QG, Humphreys H, Iro MA, Klein M, Last K, et al. European society of Clinical Microbiology and Infectious Diseases guidelines on diagnosis and treatment of brain abscess in children and adults. Clinical Microbiology and Infection. 2024;30(1):66-89. doi:10.1016/j.cmi.2023.08.016
376.
Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA. The risk of seizures among the carbapenems: a meta-analysis. Journal of Antimicrobial Chemotherapy. 2014;69(8):2043-2055. doi:10.1093/jac/dku111
377.
Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clinical Infectious Diseases. 2004;39(9):1267-1284. doi:10.1086/425368
378.
McGill F, Heyderman RS, Michael BD, Defres S, Beeching NJ, Borrow R, et al. The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults. Journal of Infection. 2016;72(4):405-438. doi:10.1016/j.jinf.2016.01.007
379.
Beek D van de, Cabellos C, Dzupova O, Esposito S, Klein M, Kloek AT, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clinical Microbiology and Infection. 2016;22:S37-S62. doi:10.1016/j.cmi.2016.01.007
380.
Tunkel AR, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Scheld WM, et al. 2017 Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clinical Infectious Diseases. 2017;64(6):e34-e65. doi:10.1093/cid/ciw861
381.
National Institute for Health and Care Excellence. Meningitis (bacterial) and meningococcal disease: Recognition, diagnosis and management (NG240). Published online March 2024. https://www.ncbi.nlm.nih.gov/books/NBK604079/bin/NG240-Methods-pdf.pdf
382.
Elyasi S, Khalili H, Dashti-Khavidaki S, Emadi-Koochak H. Conventional- versus high-dose vancomycin regimen in patients with acute bacterial meningitis: a randomized clinical trial. Expert Opinion on Pharmacotherapy. 2015;16(3):297-304. doi:10.1517/14656566.2015.999042
383.
Charlier C, Perrodeau É, Leclercq A, Cazenave B, Pilmis B, Henry B, et al. Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. The Lancet Infectious Diseases. 2017;17(5):510-519. doi:10.1016/S1473-3099(16)30521-7
384.
Beek D van de, Brouwer MC, Koedel U, Wall EC. Community-acquired bacterial meningitis. The Lancet. 2021;398(10306):1171-1183. doi:10.1016/S0140-6736(21)00883-7
385.
Brouwer MC, McIntyre P, Prasad K, Beek D van de. Corticosteroids for acute bacterial meningitis. Cochrane Database of Systematic Reviews. 2015;(9):CD004405. doi:10.1002/14651858.CD004405.pub5
386.
Samkar A van, Brouwer MC, Schultsz C, Ende A van der, Beek D van de. Streptococcus suis meningitis: A systematic review and meta-analysis. PLOS Neglected Tropical Diseases. 2015;9(10):e0004191. doi:10.1371/journal.pntd.0004191
387.
Syrogiannopoulos GA, Lourida AN, Theodoridou MC, Pappas IG, Babilis GC, Economidis JJ, et al. Dexamethasone therapy for bacterial meningitis in children: 2-versus 4-day regimen. Journal of Infectious Diseases. 1994;169(4):853-858. doi:10.1093/infdis/169.4.853
388.
Bijlsma MW, Brouwer MC, Kasanmoentalib ES, Kloek AT, Lucas MJ, Tanck MW, et al. Community-acquired bacterial meningitis in adults in the Netherlands, 2006–14: a prospective cohort study. The Lancet Infectious Diseases. 2016;16(3):339-347. doi:10.1016/S1473-3099(15)00430-2
389.
Hsueh PR. Study for Monitoring Antimicrobial Resistance Trends (SMART) in the Asia-Pacific region, 2002-2010. International Journal of Antimicrobial Agents. 2012;40 Suppl 1:S1-3. doi:10.1016/S0924-8579(12)00244-0
390.
Liu YM, Chen YS, Toh HS, Huang CC, Lee YL, Ho CM, et al. In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). International Journal of Antimicrobial Agents. 2012;40 Suppl 1:S11-17. doi:10.1016/S0924-8579(12)70004-3
391.
Montravers P, Dupont H, Leone M, Constantin JM, Mertes PM, Laterre PF, et al. Guidelines for management of intra-abdominal infections. Anaesthesia Critical Care & Pain Medicine. 2015;34(2):117-130. doi:10.1016/j.accpm.2015.03.005
392.
Sartelli M, Chichom-Mefire A, Labricciosa FM, Hardcastle T, Abu-Zidan FM, Adesunkanmi AK, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. World Journal of Emergency Surgery. 2017;12(29):1-34. doi:10.1186/s13017-017-0141-6
393.
Ho PL, Yau CY, Ho LY, Lai ELY, Liu MCJ, Tse CWS, et al. Antimicrobial susceptibility of Bacteroides fragilis group organisms in Hong Kong by the tentative EUCAST disc diffusion method. Anaerobe. 2017;47:51-56. doi:10.1016/j.anaerobe.2017.04.005
394.
Gomi H, Solomkin JS, Schlossberg D, Okamoto K, Takada T, Strasberg SM, et al. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. Journal of Hepato-Biliary-Pancreatic Sciences. 2018;25(1):3-16. doi:10.1002/jhbp.518
395.
Kumanan T, Sujanitha V, Sreeharan N. Amoebic liver abscess: a neglected tropical disease. The Lancet Infectious Diseases. 2020;20(2):160-162. doi:10.1016/S1473-3099(19)30696-6
396.
Mohsen AH, Green ST, Read RC, McKendrick MW. Liver abscess in adults: ten years experience in a UK centre. QJM: An International Journal of Medicine. 2002;95(12):797-802. doi:10.1093/qjmed/95.12.797
397.
Usuda D, Tsuge S, Sakurai R, Kawai K, Matsubara S, Tanaka R, et al. Amebic liver abscess by Entamoeba histolytica. World Journal of Clinical Cases. 2022;10(36):13157-13166. doi:10.12998/wjcc.v10.i36.13157
398.
Richardson D, Pakianathan M, Ewens M, Mitchell H, Mohammed H, Wiseman E, et al. British Association of Sexual Health and HIV (BASHH) United Kingdom national guideline for the management of sexually transmitted enteric infections 2023. International Journal of STD & AIDS. 2023;34(9):588-602. doi:10.1177/09564624231168217
399.
Cooney J, Siakavellas SI, Chiodini PL, Mahadeva U, Godbole G, Pollok RCG, et al. Recent advances in the diagnosis and management of amoebiasis. Frontline Gastroenterology. 2025;16(1):37-50. doi:10.1136/flgastro-2023-102554
400.
Lok KH, Li KF, Li KK, Szeto ML. Pyogenic liver abscess: clinical profile, microbiological characteristics, and management in a Hong Kong hospital. Journal of Microbiology, Immunology, and Infection. 2008;41(6):483-490. https://pubmed.ncbi.nlm.nih.gov/19255692
401.
Chiu CT, Lin DY, Liaw YF. Metastatic septic endophthalmitis in pyogenic liver abscess. Journal of Clinical Gastroenterology. 1988;10(5):524-527. doi:10.1097/00004836-198810000-00009
402.
Fang CT, Lai SY, Yi WC, Hsueh PR, Liu KL, Chang SC. Klebsiella pneumoniae genotype K1: an emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess. Clinical Infectious Diseases. 2007;45(3):284-293. doi:10.1086/519262
403.
Fung CP, Chang FY, Lee SC, Hu BS, Kuo BIT, Liu CY, et al. A global emerging disease of Klebsiella pneumoniae liver abscess: is serotype K1 an important factor for complicated endophthalmitis? Gut. 2002;50(3):420-424. doi:10.1136/gut.50.3.420
404.
Lee SSJ, Chen YS, Tsai HC, Wann SR, Lin HH, Huang CK, et al. Predictors of septic metastatic infection and mortality among patients with Klebsiella pneumoniae liver abscess. Clinical Infectious Diseases. 2008;47(5):642-650. doi:10.1086/590932
405.
Sheu SJ, Kung YH, Wu TT, Chang FP, Horng YH. Risk factors for endogenous endophthalmitis secondary to Klebsiella pneumoniae liver abscess: 20-year experience in Southern Taiwan. Retina. 2011;31(10):2026-2031. doi:10.1097/IAE.0b013e31820d3f9e
406.
Sng CC, Jap A, Chan YH, Chee SP. Risk factors for endogenous Klebsiella endophthalmitis in patients with Klebsiella bacteraemia: a case-control study. British Journal of Ophthalmology. 2008;92(5):673-677. doi:10.1136/bjo.2007.132522
407.
Lee JY, Kim KH. Endogenous endophthalmitis complicated by pyogenic liver abscess: a review of 17 years’ experience at a single center. Digestion. 2014;90(2):116-121. doi:10.1159/000367649
408.
Shane AL, Mody RK, Crump JA, Tarr PI, Steiner TS, Kotloff K, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clinical Infectious Diseases. 2017;65(12):e45-e80. doi:10.1093/cid/cix669
409.
Farthing M, Salam MA, Lindberg G, Dite P, Khalif I, Salazar-Lindo E, et al. Acute diarrhea in adults and children: a global perspective. Journal of Clinical Gastroenterology. 2013;47(1):12-20. doi:10.1097/MCG.0b013e31826df662
410.
DuPont HL. Acute infectious diarrhea in immunocompetent adults. The New England Journal of Medicine. 2014;370(16):1532-1540. doi:10.1056/NEJMra1301069
411.
Barr W, Smith A. Acute diarrhea in adults. American Family Physician. 2014;89(3):180-189. https://www.aafp.org/pubs/afp/issues/2014/0201/p180.html
412.
Zollner-Schwetz I, Krause R. Therapy of acute gastroenteritis: role of antibiotics. Clinical Microbiology and Infection. 2015;21(8):744-749. doi:10.1016/j.cmi.2015.03.002
413.
Riddle MS, DuPont HL, Connor BA. ACG clinical guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. The American Journal of Gastroenterology. 2016;111(5):602-622. doi:10.1038/ajg.2016.126
414.
Kaakoush NO, Castaño-Rodríguez N, Mitchell HM, Man SM. Global epidemiology of Campylobacter infection. Clinical Microbiology Reviews. 2015;28(3):687-720. doi:10.1128/CMR.00006-15
415.
Li X, Cao H, Chen JHK, Ng YZ, Fung KK, Cheng VCC, et al. Genomic Investigation of Salmonella Typhi in Hong Kong Revealing the Predominance of Genotype 3.2.2 and the First Case of an Extensively Drug-Resistant H58 Genotype. Microorganisms. 2023;11(3):667. doi:10.3390/microorganisms11030667
416.
Centre for Health Protection, Department of Health, the Government of the Hong Kong Special Administrative Region. Bacterial pathogen isolation and percentage of antimicrobial resistance - out-patient setting. Published online 2023. Accessed December 20, 2024. https://www.chp.gov.hk/en/statistics/data/10/641/697/3345.html
417.
Pfizer Laboratories Div Pfizer Inc. LOMOTIL - diphenoxylate hydrochloride and atropine sulfate tablet. Published online September 2023. https://dailymed.nlm.nih.gov/dailymed
/drugInfo.cfm?setid=f170584a-1072-4fd7-b1dc-6756703483b9
418.
United States Food and Drug Administration. IMODIUM (loperamide hydrochloride) Label. Published online 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017694s052lbl.pdf
419.
Riddle MS, Connor BA, Beeching NJ, DuPont HL, Hamer DH, Kozarsky P, et al. Guidelines for the prevention and treatment of travelers’ diarrhea: a graded expert panel report. Journal of Travel Medicine. 2017;24(suppl_1):S63-S80. doi:10.1093/jtm/tax026
420.
Steffen R, Hill DR, DuPont HL. Traveler’s diarrhea: a clinical review. JAMA. 2015;313(1):71-80. doi:10.1001/jama.2014.17006
421.
Giddings SL, Stevens AM, Leung DT. Traveler’s Diarrhea. Medical Clinics of North America. 2016;100(2):317-330. doi:10.1016/j.mcna.2015.08.017
422.
Arcilla MS, Hattem JM van, Haverkate MR, Bootsma MCJ, Genderen PJJ van, Goorhuis A, et al. Import and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): a prospective, multicentre cohort study. The Lancet Infectious Diseases. 2017;17(1):78-85. doi:10.1016/S1473-3099(16)30319-X
423.
Prevention CDC, Nemhauser JB. CDC Yellow Book 2024: Health Information for International Travel. Oxford University Press; 2023. https://books.google.com.hk/books?id=mSezEAAAQBAJ
424.
Qamar FN, Azmatullah A, Kazi AM, Khan E, Zaidi AKM. A three-year review of antimicrobial resistance of Salmonella enterica serovars Typhi and Paratyphi A in Pakistan. Journal of Infection in Developing Countries. 2014;8(8):981-986. doi:10.3855/jidc.3817
425.
Rasheed F, Saeed M, Alikhan NF, Baker D, Khurshid M, Ainsworth EV, et al. Emergence of Resistance to Fluoroquinolones and Third-Generation Cephalosporins in Salmonella Typhi in Lahore, Pakistan. Microorganisms. 2020;8(9):1336. doi:10.3390/microorganisms8091336
426.
Brouqui P, Raoult D. New insight into the diagnosis of fastidious bacterial endocarditis. FEMS Immunology and Medical Microbiology. 2006;47(1):1-13. doi:10.1111/j.1574-695X.2006.00054.x
427.
Gould FK, Denning DW, Elliott TS, Foweraker J, Perry JD, Prendergast BD, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. Journal of Antimicrobial Chemotherapy. 2012;67(2):269-289. doi:10.1093/jac/dkr450
428.
Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin III JP, Gentile F, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e35-e71. doi:10.1161/CIR.0000000000000932
429.
Chambers HF, Bayer AS. Native-Valve Infective Endocarditis. The New England Journal of Medicine. 2020;383(6):567-576. doi:10.1056/NEJMcp2000400
430.
Cahill TJ, Prendergast BD. Infective endocarditis. The Lancet. 2016;387(10021):882-893. doi:10.1016/S0140-6736(15)00067-7
431.
Delgado V, Ajmone Marsan N, Waha S de, Bonaros N, Brida M, Burri H, et al. 2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM). European Heart Journal. 2023;44(39):3948-4042. doi:10.1093/eurheartj/ehad193
432.
Baddour LM, Wilson WR, Bayer AS, Fowler Jr VG, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435-1486. doi:10.1161/CIR.0000000000000296
433.
Bolger AF. Infective Endocarditis. In: Fuster V, Narula J, Vaishnava P, Leon MB, Callans DJ, Rumsfeld JS, Poppas A. eds. Fuster and Hurst’s The Heart, 15e. McGraw-Hill Education; 2022. Accessed December 20, 2024. https://accessmedicine.mhmedical.com/content.aspx?bookid=3134§ionid=265675472
434.
Fowler Jr VG, Durack DT, Selton-Suty C, Athan E, Bayer AS, Chamis AL, et al. The 2023 Duke-International Society for Cardiovascular Infectious Diseases criteria for infective endocarditis: updating the modified Duke criteria. Clinical Infectious Diseases. 2023;77(4):518-526. doi:10.1093/cid/ciad271
435.
Centre for Health Protection, Department of Health, the Government of the Hong Kong Special Administrative Region. Statistics on Communicable Diseases: Number of Notifiable Infectious Diseases by Month. Published online 2024. Accessed December 20, 2024. https://www.chp.gov.hk/en/static/24012.html
436.
Sanaiha Y, Lyons R, Benharash P. Infective endocarditis in intravenous drug users. Trends in Cardiovascular Medicine. 2020;30(8):491-497. doi:10.1016/j.tcm.2019.11.007
437.
Ross J, Guaschino S, Cusini M, Jensen J. 2017 European guideline for the management of pelvic inflammatory disease. International Journal of STD & AIDS. 2018;29(2):108-114. doi:10.1177/0956462417744099
438.
Brun JL, Castan B, Barbeyrac B de, Cazanave C, Charvériat A, Faure K, et al. Pelvic inflammatory diseases: Updated French guidelines. Journal of Gynecology Obstetrics and Human Reproduction. 2020;49(5):101714. doi:10.1016/j.jogoh.2020.101714
439.
Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. Morbidity and Mortality Weekly Report Recommendations and reports. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1
440.
Ross J, Cole M, Evans C, Lyons D, Dean G, Cousins D, et al. United Kingdom National Guideline for the Management of Pelvic Inflammatory Disease (2019 Interim Update). Published online 2019. https://www.bashh.org/_userfiles/pages/files/resources/pidupdate2019.pdf
441.
Dowell D, Kirkcaldy RD. Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis. Sexually Transmitted Infections. 2012;88(8):589-594. doi:10.1136/sextrans-2012-050604
442.
Ross JDC, Brittain C, Cole M, Dewsnap C, Harding J, Hepburn T, et al. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial. The Lancet. 2019;393(10190):2511-2520. doi:10.1016/S0140-6736(18)32817-4
443.
Walker CK, Workowski KA, Washington AE, Soper D, Sweet RL. Anaerobes in pelvic inflammatory disease: implications for the Centers for Disease Control and Prevention’s guidelines for treatment of sexually transmitted diseases. Clinical Infectious Diseases. 1999;28(Supplement_1):S29-S36. doi:10.1086/514720
444.
Lo JYC, Ho KM, Lo ACT. Surveillance of gonococcal antimicrobial susceptibility resulting in early detection of emerging resistance. Journal of Antimicrobial Chemotherapy. 2012;67(6):1422-1426. doi:10.1093/jac/dks036
445.
Ho PL. The best of times, the worst of times, and emerging gonococcal multidrug resistance. Hong Kong Journal of Dermatology & Venereology. 2011;19:163-166. https://medcomhk.com/hkdvb/pdf/2011v19n04-01.pdf
446.
Boakes E, Woods A, Johnson N, Kadoglou N. Breast Infection: A Review of Diagnosis and Management Practices. European Journal of Breast Health. 2018;14(3):136-143. doi:10.5152/ejbh.2018.3871
447.
Lam E, Chan T, Wiseman SM. Breast abscess: evidence based management recommendations. Expert Review of Anti-infective Therapy. 2014;12(7):753-762. doi:10.1586/14787210.2014.913982
448.
Ammann AM, Pratt CG, Lewis JD, Ahmad SA, Shaughnessy E, Heelan AA. Breast infections: A review of current literature. The American Journal of Surgery. 2024;228:78-82. doi:10.1016/j.amjsurg.2023.10.040
449.
Jaworsky D, Reynolds S, Chow AW. Extracranial head and neck infections. Critical Care Clinics. 2013;29(3):443-463. doi:10.1016/j.ccc.2013.03.003
450.
Yang W, Hu L, Wang Z, Nie G, Li X, Lin D, et al. Deep neck infection: A review of 130 cases in Southern China. Medicine. 2015;94(27):e994. doi:10.1097/MD.0000000000000994
451.
Japanese Association for Infectious Disease/Japanese Society of Chemotherapy, JAID/JSC Committee for Developing Treatment Guide and Guidelines for Clinical Management of Infectious Disease, Odontogenic Infection Working Group. The 2016 JAID/JSC guidelines for clinical management of infectious disease-Odontogenic infections. Journal of Infection and Chemotherapy. 2018;24(5):320-324. doi:10.1016/j.jiac.2017.09.014
452.
Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review. JAMA. 2014;312(16):1677-1684. doi:10.1001/jama.2014.12842
453.
Al Lawati H, Blair BM, Larnard J. Urinary tract infections: core curriculum 2024. American Journal of Kidney Diseases. 2024;83(1):90-100. doi:10.1053/j.ajkd.2023.08.009
454.
Kranz J, Bartoletti R, Bruyère F, Cai T, Geerlings S, Köves B, et al. European Association of Urology Guidelines on Urological Infections: Summary of the 2024 Guidelines. European Urology. 2024;86(1):27-41. doi:10.1016/j.eururo.2024.03.035
455.
American Geriatrics Society 2015 Beers Criteria Update Expert Panel, Fick DM, Semla TP, Beizer J, Brandt N, Dombrowski R, et al. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2015;63(11):2227-2246. doi:10.1111/jgs.18372
456.
Shigemura K, Ishikawa K. AAUS guideline for acute uncomplicated pyelonephritis. Journal of Infection and Chemotherapy. 2022;28(8):1092-1097. doi:10.1016/j.jiac.2022.05.008
457.
National Institute for Health and Care Excellence. Pyelonephritis (acute): antimicrobial prescribing. Published online October 2018. https://www.nice.org.uk/guidance/ng111
458.
Jacobs DM, Pandit U, Sethi S. Acute exacerbations in chronic obstructive pulmonary disease: should we use antibiotics and if so, which ones? Current Opinion in Infectious Diseases. 2019;32(2):143-151. doi:10.1097/QCO.0000000000000533
459.
Leung V, Lee C. Shorter duration of antibiotic therapy for exacerbation of COPD. European Respiratory Journal. 2023;61(6):2300455. doi:10.1183/13993003.00455-2023
460.
Wedzicha JA, Miravitlles M, Hurst JR, Calverley PMA, Albert RK, Anzueto A, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal. 2017;49(3):1600791. doi:10.1183/13993003.00791-2016
462.
Ko FW, Chan KP, Hui DS, Goddard JR, Shaw JG, Reid DW, et al. Acute exacerbation of COPD. Respirology. 2016;21(7):1152-1165. doi:10.1111/resp.12780
463.
Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. International Journal of Antimicrobial Agents. 2001;18(6):503-512. doi:10.1016/s0924-8579(01)00435-6
464.
Llor C, Moragas A, Miravitlles M, Mesquita P, Cordoba G. Are short courses of antibiotic therapy as effective as standard courses for COPD exacerbations? A systematic review and meta-analysis. Pulmonary Pharmacology & Therapeutics. 2022;72:102111. doi:10.1016/j.pupt.2022.102111
465.
Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn SJ, Floto AR, et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):1-69. doi:10.1136/thoraxjnl-2018-212463
466.
Haworth CS, Floto RA. Antibiotic Management in Bronchiectasis. Clinics in Chest Medicine. 2022;43(1):165-177. doi:10.1016/j.ccm.2021.11.009
467.
Chang AB, Bell SC, Byrnes CA, Dawkins P, Holland AE, Kennedy E, et al. Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand. Respirology. 2023;28(4):339-349. doi:10.1111/resp.14479
468.
O’Donnell AE. Bronchiectasis - A Clinical Review. The New England Journal of Medicine. 2022;387(6):533-545. doi:10.1056/NEJMra2202819
469.
Mandell LA, Niederman MS. Aspiration Pneumonia. The New England Journal of Medicine. 2019;380(7):651-663. doi:10.1056/NEJMra1714562
470.
Bai AD, Srivastava S, Digby GC, Girard V, Razak F, Verma AA. Anaerobic Antibiotic Coverage in Aspiration Pneumonia and the Associated Benefits and Harms: A Retrospective Cohort Study. Chest. 2024;166(1):39-48. doi:10.1016/j.chest.2024.02.025
471.
File TM, Ramirez JA. Community-Acquired Pneumonia. O’Malley PG, ed. The New England Journal of Medicine. 2023;389(7):632-641. doi:10.1056/nejmcp2303286
472.
National Institute for Health and Care Excellence. Pneumonia (community-acquired): antimicrobial prescribing. Published online September 2019. https://www.nice.org.uk/guidance/ng138
473.
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST
474.
Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64 Suppl 3:iii1-55. doi:10.1136/thx.2009.121434
475.
Martin-Loeches I, Torres A, Nagavci B, Aliberti S, Antonelli M, Bassetti M, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Medicine. 2023;49(6):615-632. doi:10.1007/s00134-023-07033-8
476.
Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic therapy for adults hospitalized with community-acquired pneumonia: A systematic review. JAMA. 2016;315(6):593-602. doi:10.1001/jama.2016.0115
477.
Ho PL, Yam WC, Que TL, Tsang DNC, Seto WH, Ng TK, et al. Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones. Journal of Antimicrobial Chemotherapy. 2001;47(5):655-658. doi:10.1093/jac/47.5.655
478.
Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353
479.
Liapikou A, Rosales-Mayor E, Torres A. Pharmacotherapy for hospital-acquired pneumonia. Expert Opinion on Pharmacotherapy. 2014;15(6):775-786. doi:10.1517/14656566.2014.889115
480.
Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). European Respiratory Journal. 2017;50(3):1700582. doi:10.1183/13993003.00582-2017
481.
National Institute for Health and Care Excellence. Pneumonia (hospital-acquired): antimicrobial prescribing. Published online September 2019. https://www.nice.org.uk/guidance/ng139
482.
Dessajan J, Timsit JF. Impact of multiplex PCR in the therapeutic management of severe bacterial pneumonia. Antibiotics. 2024;13(1):95. doi:10.3390/antibiotics13010095
483.
Darie AM, Khanna N, Jahn K, Osthoff M, Bassetti S, Osthoff M, et al. Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial. The Lancet Respiratory Medicine. 2022;10(9):877-887. doi:10.1016/s2213-2600(22)00086-8
484.
Markussen DL, Serigstad S, Ritz C, Knoop ST, Ebbesen MH, Faurholt-Jepsen D, et al. Diagnostic Stewardship in Community-Acquired Pneumonia With Syndromic Molecular Testing: A Randomized Clinical Trial. JAMA Network Open. 2024;7(3):e240830. doi:10.1001/jamanetworkopen.2024.0830
485.
Cillóniz C, Torres A, Niederman M, Eerden M van der, Chalmers J, Welte T, et al. Community-acquired pneumonia related to intracellular pathogens. Intensive Care Medicine. 2016;42(9):1374-1386. doi:10.1007/s00134-016-4394-4
486.
Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia. 2020;12:11. doi:10.1186/s41479-020-00074-3
487.
Gadsby NJ, Musher DM. The Microbial Etiology of Community-Acquired Pneumonia in Adults: from Classical Bacteriology to Host Transcriptional Signatures. Clinical Microbiology Reviews. 2022;35(4):e00015-22. doi:10.1128/cmr.00015-22
488.
Kim K, Jung S, Kim M, Park S, Yang HJ, Lee E. Global trends in the proportion of macrolide-resistant mycoplasma pneumoniae infections: a systematic review and meta-analysis. JAMA Network Open. 2022;5(7):e2220949. doi:10.1001/jamanetworkopen.2022.20949
489.
Oishi T, Ouchi K. Recent Trends in the Epidemiology, Diagnosis, and Treatment of Macrolide-Resistant Mycoplasma pneumoniae. Journal of Clinical Medicine. 2022;11(7):1782. doi:10.3390/jcm11071782
490.
Chen YC, Hsu WY, Chang TH. Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia. Emerging Infectious Diseases. 2020;26(7):1382-1391. doi:10.3201/eid2607.200017
491.
Lee H, Choi YY, Sohn YJ, Kim YK, Han MS, Yun KW, et al. Clinical efficacy of doxycycline for treatment of Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Children. Antibiotics. 2021;10(2):192. doi:10.3390/antibiotics10020192
492.
Song JH, Huh K, Chung DR. Community-Acquired Pneumonia in the Asia-Pacific Region. Seminars in Respiratory and Critical Care Medicine. 2016;37(6):839-854. doi:10.1055/s-0036-1592075
493.
Gassiep I, Armstrong M, Norton R. Human Melioidosis. Clinical Microbiology Reviews. 2020;33(2):e00006-19. doi:10.1128/CMR.00006-19
494.
Lui G, Tam A, Tso EYK, Wu AKL, Zee J, Choi KW, et al. Melioidosis in Hong Kong. Tropical Medicine and Infectious Disease. 2018;3(3):91. doi:10.3390/tropicalmed3030091
495.
Wu WG, Shum MHH, Wong ITF, Lu KK, Lee LK, Leung JSL, et al. Probable airborne transmission of Burkholderia pseudomallei causing an urban outbreak of melioidosis during typhoon season in Hong Kong, China. Emerging Microbes & Infections. 2023;12(1):2204155. doi:10.1080/22221751.2023.2204155
496.
Chiu W, Lin W. Latest situation of melioidosis in Hong Kong. Communicable Diseases Watch. 2024;20(2):6-7. https://www.chp.gov.hk/files/pdf/cdw_v20_2.pdf
497.
Friedland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. The Pediatric Infectious Disease Journal. 1995;14(10):885-890. doi:10.1097/00006454-199510000-00013
498.
Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. The New England Journal of Medicine. 1995;333(8):474-480. doi:10.1056/NEJM199508243330802
499.
Metlay JP, Hofmann JO, Cetron MS, Fine MJ, Farley MM, Whitney C, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clinical Infectious Diseases. 2000;30(3):520-528. doi:10.1086/313716
500.
Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clinical Infectious Diseases. 1999;29(2):321-327. doi:10.1086/520209
501.
Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. American Journal of Public Health. 2000;90(2):223-229. doi:10.2105/ajph.90.2.223
502.
Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clinical Infectious Diseases. 2009;48(11):1596-1600. doi:10.1086/598975
503.
Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Archives of Internal Medicine. 2000;160(10):1399-1408. doi:10.1001/archinte.160.10.1399
504.
Peterson LR. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? Clinical Infectious Diseases. 2006;42(2):224-233. doi:10.1086/497594
505.
Kim L, McGee L, Tomczyk S, Beall B. Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective. Clinical Microbiology Reviews. 2016;29(3):525-552. doi:10.1128/CMR.00058-15
506.
Ho PL, Que TL, Tsang DNC, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrobial Agents and Chemotherapy. 1999;43(5):1310-1313. doi:10.1128/AAC.43.5.1310
507.
Ho PL, Yung RWH, Tsang DNC, Que TL, Ho M, Seto WH, et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. Journal of Antimicrobial Chemotherapy. 2001;48(5):659-665. doi:10.1093/jac/48.5.659
508.
Ho PL, Chiu SS, Ang I, Lau YL. Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae before and after introduction of 7-valent pneumococcal conjugate vaccine, Hong Kong, 1995-2009. Vaccine. 2011;29(17):3270-3275. doi:10.1016/j.vaccine.2011.02.025
509.
Ho PL, Chiu SS, Law PY, Chan EL, Lai EL, Chow KH. Increase in the nasopharyngeal carriage of non-vaccine serogroup 15 Streptococcus pneumoniae after introduction of children pneumococcal conjugate vaccination in Hong Kong. Diagnostic Microbiology and Infectious Disease. 2015;81(2):145-148. doi:10.1016/j.diagmicrobio.2014.11.006
510.
Liyanapathirana V, Nelson EA, Ang I, Subramanian R, Ma H, Ip M. Emergence of serogroup 15 Streptococcus pneumoniae of diverse genetic backgrounds following the introduction of pneumococcal conjugate vaccines in Hong Kong. Diagnostic Microbiology and Infectious Disease. 2015;81(1):66-70. doi:10.1016/j.diagmicrobio.2014.09.028
511.
Boost MV, O’Donoghue MM, Dooley JS. Prevalence of carriage of antimicrobial resistant strains of streptococcus pneumoniae in primary school children in Hong Kong. Epidemiology and Infection. 2001;127(1):49-55. doi:10.1017/s0950268801005647
512.
Chiu SS, Ho PL, Chow FK, Yuen KY, Lau YL. Nasopharyngeal carriage of antimicrobial-resistant Streptococcus pneumoniae among young children attending 79 kindergartens and day care centers in Hong Kong. Antimicrobial Agents and Chemotherapy. 2001;45(10):2765-2770. doi:10.1128/AAC.45.10.2765-2770.2001
513.
Ho PL, Chiu SS, Chan MY, Ang I, Chow KH, Lau YL. Changes in nasopharyngeal carriage and serotype distribution of antibiotic-resistant Streptococcus pneumoniae before and after the introduction of 7-valent pneumococcal conjugate vaccine in Hong Kong. Diagnostic Microbiology and Infectious Disease. 2011;71(4):327-334. doi:10.1016/j.diagmicrobio.2011.09.006
514.
Chan KC, Subramanian R, Chong P, Nelson EA, Lam HS, Li AM, et al. Pneumococcal carriage in young children after introduction of PCV13 in Hong Kong. Vaccine. 2016;34(33):3867-3874. doi:10.1016/j.vaccine.2016.05.047
515.
Chan KC, Ip M, Chong PS, Li AM, Lam HS, Nelson EA. Nasopharyngeal colonisation and antimicrobial resistance of Streptococcus pneumoniae in Hong Kong children younger than 2 years. Hong Kong Medical Journal. 2018;24(Supplement 6):S4-7. https://www.hkmj.org/abstracts/v24%20Suppl%206n5/4.htm
516.
Ip M, Lyon DJ, Yung RWH, Chan C, Cheng AFB. Evidence of clonal dissemination of multidrug-resistant Streptococcus pneumoniae in Hong Kong. Journal of Clinical Microbiology. 1999;37(9):2834-2839. doi:10.1128/JCM.37.9.2834-2839.1999
517.
Lyon DJ, Scheel O, Fung KS, Cheng AF, Henrichsen J. Rapid emergence of penicillin-resistant pneumococci in Hong Kong. Scandinavian Journal of Infectious Diseases. 1996;28(4):375-376. doi:10.3109/00365549609037922
518.
Wong SSY, Woo PCY, Ho PL, Cheng VCC, Yuen KY. Emergence of Streptococcus pneumoniae with high-level resistance to cefotaxime in Hong Kong. Hong Kong Medical Journal. 1999;5(4):406-409. https://www.hkmj.org/abstracts/v5n4/406.htm
519.
Kang CI, Song JH, Kim SH, Chung DR, Peck KR, So TM, et al. Risk factors for levofloxacin-nonsusceptible Streptococcus pneumoniae in community-acquired pneumococcal pneumonia: a nested case-control study. European Journal of Clinical Microbiology & Infectious Diseases. 2014;33(1):55-59. doi:10.1007/s10096-013-1928-3
520.
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement. Published online 2004.
521.
Ho PL, Tse WS, Tsang KWT, Kwok TK, Ng TK, Cheng VCC, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clinical Infectious Diseases. 2001;32(5):701-707. doi:10.1086/319222
522.
Tsang KW, File TMJ. Respiratory infections unique to Asia. Respirology. 2008;13(7):937-949. doi:10.1111/j.1440-1843.2008.01409.x
523.
Sterling TR. The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls. The International Journal of Tuberculosis and Lung Disease. 2004;8(12):1396-1400. https://pubmed.ncbi.nlm.nih.gov/15636484
524.
Dooley KE, Golub J, Goes FS, Merz WG, Timothy SR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clinical Infectious Diseases. 2002;34(12):1607-1612. doi:10.1086/340618
525.
Chang KC, Leung CC, Yew WW, Lau TY, Leung WM, Tam CM, et al. Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? European Respiratory Journal. 2010;35(3):606-613. doi:10.1183/09031936.00104209
526.
Committee on Infectious Diseases AA of P, Kimberlin DW, Banerjee R, Barnett ED, Lynfield R, Sawyer MH. Red Book: 2024–2027 Report of the Committee on Infectious Diseases. American Academy of Pediatrics; 2024. doi:10.1542/9781610027373
527.
Talan DA, Mower WR, Krishnadasan A, Abrahamian FM, Lovecchio F, Karras DJ, et al. Trimethoprim–sulfamethoxazole versus placebo for uncomplicated skin abscess. New England Journal of Medicine. 2016;374(9):823-832. doi:10.1056/NEJMoa1507476
528.
Daum RS, Miller LG, Immergluck L, Fritz S, Creech CB, Young D, et al. A placebo-controlled trial of antibiotics for smaller skin abscesses. New England Journal of Medicine. 2017;376(26):2545-2555. doi:10.1056/NEJMoa1607033
529.
Prehn J van, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clinical Microbiology and Infection. 2021;27:S1-S21. doi:10.1016/j.cmi.2021.09.038
530.
Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, Vos WM de, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. The New England Journal of Medicine. 2013;368(5):407-415. doi:10.1056/NEJMoa1205037
531.
Ho PL, Shek RHL, Chow KH, Duan RS, Mak GC, Lai EL, et al. Detection and characterization of extended-spectrum β-lactamases among bloodstream isolates of Enterobacter spp. in Hong Kong, 2000-2002. Journal of Antimicrobial Chemotherapy. 2005;55(3):326-332. doi:10.1093/jac/dki010
532.
Onorato L, Macera M, Calò F, Cirillo P, Di Caprio G, Coppola N. Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to Pseudomonas aeruginosa: a meta-analysis. International Journal of Antimicrobial Agents. 2022;59(3):106512. doi:10.1016/j.ijantimicag.2021.106512
533.
Centre for Health Protection, Department of Health, the Government of the Hong Kong Special Administrative Region. Detection of pathogens from respiratory specimens. Published online 2024. Accessed December 20, 2024. https://www.chp.gov.hk/en/statistics/data/10/641/642/2274.html
534.
Araoka H, Baba M, Okada C, Abe M, Kimura M, Yoneyama A. Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients. International Journal of Infectious Diseases. 2017;58:18-21. doi:10.1016/j.ijid.2017.02.020
535.
Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. American Journal of Health-System Pharmacy. 2013;70(3):195-283. doi:10.2146/ajhp120568
536.
Anderson DJ. Antimicrobial prophylaxis for prevention of surgical site infection in adults - UpToDate. Published online October 2022. Accessed December 20, 2024. https://ffr.uptodate.com/contents
/antimicrobial-prophylaxis-for-prevention-of-surgical-site-infection-in-adults
/print
537.
Centers for Disease Control and Prevention. Surgical Site Infection Event (SSI) Protocol.; 2024. https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf
538.
Paterson DL. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clinical Infectious Diseases. 2004;38(Supplement_4):S341-S345. doi:10.1086/382690
539.
Weber WP, Mujagic E, Zwahlen M, Bundi M, Hoffmann H, Soysal SD, et al. Timing of surgical antimicrobial prophylaxis: a phase 3 randomised controlled trial. The Lancet Infectious Diseases. 2017;17(6):605-614. doi:10.1016/S1473-3099(17)30176-7
540.
Sommerstein R, Troillet N, Harbarth S, Kraker MEA de, Vuichard-Gysin D, Kuster SP, et al. Timing of cefuroxime surgical antimicrobial prophylaxis and its association with surgical site infections. JAMA Network Open. 2023;6(6):e2317370. doi:10.1001/jamanetworkopen.2023.17370
541.
Humphreys H, Becker K, Dohmen PM, Petrosillo N, Spencer M, Van Rijen M, et al. Staphylococcus aureus and surgical site infections: benefits of screening and decolonization before surgery. Journal of Hospital Infection. 2016;94(3). doi:10.1016/j.jhin.2016.06.011
542.
Edmiston CE, Ledeboer NA, Buchan BW, Spencer M, Seabrook GR, Leaper D. Is Staphylococcal Screening and Suppression an Effective Interventional Strategy for Reduction of Surgical Site Infection? Surgical Infections. 2016;17(2). doi:10.1089/sur.2015.257
543.
Steinberg JP, Braun BI, Hellinger WC, Kusek L, Bozikis MR, Bush AJ, et al. Timing of antimicrobial prophylaxis and the risk of surgical site infections: results from the Trial to Reduce Antimicrobial Prophylaxis Errors. Annals of Surgery. 2009;250(1):10-16. doi:10.1097/SLA.0b013e3181ad5fca
544.
Zelenitsky SA, Ariano RE, Harding GKM, Silverman RE. Antibiotic pharmacodynamics in surgical prophylaxis: an association between intraoperative antibiotic concentrations and efficacy. Antimicrobial Agents and Chemotherapy. 2002;46(9):3026-3030. doi:10.1128/AAC.46.9.3026-3030.2002
545.
Zanetti G, Giardina R, Platt R. Intraoperative Redosing of Cefazolin and Risk for Surgical Site Infection in Cardiac Surgery. Emerging Infectious Diseases. 2001;7(5):828-831. doi:10.3201/eid0705.017509
546.
Health Products Regulatory Authority. Product Authorisation: PA1077/093/002. Published online January 2020. Accessed December 20, 2024. https://www.hpra.ie/img/uploaded/swedocuments
/Licence_PA1077-093-002_16012020113227.pdf
547.
Blum S, Cunha CB, Cunha BA. Lack of pharmacokinetic basis of weight-based dosing and intra-operative re-dosing with cefazolin surgical prophylaxis in obese patients: implications for antibiotic stewardship. Surgical Infections. 2019;20(6):439-443. doi:10.1089/sur.2019.039
548.
Coates M, Shield A, Peterson GM, Hussain Z. Prophylactic cefazolin dosing in obesity—a systematic review. Obesity Surgery. 2022;32(9):3138-3149. doi:10.1007/s11695-022-06196-5
549.
Berríos-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surgery. 2017;152(8):784-791. doi:10.1001/jamasurg.2017.0904
550.
Blumenthal KG, Ryan EE, Li Y, Lee H, Kuhlen JL, Shenoy ES. The impact of a reported penicillin allergy on surgical site infection risk. Clinical Infectious Diseases. 2018;66(3):329-336. doi:10.1093/cid/cix794
551.
Lam PW, Tarighi P, Elligsen M, Gunaratne K, Nathens AB, Tarshis J, et al. Self-reported beta-lactam allergy and the risk of surgical site infection: a retrospective cohort study. Infection Control & Hospital Epidemiology. 2020;41(4):438-443. doi:10.1017/ice.2019.374
552.
Righi E, Mutters NT, Guirao X, Del Toro MD, Eckmann C, Friedrich AW, et al. ESCMID/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery. Clinical Microbiology and Infection. 2023;29(4):463-479. doi:10.1016/j.cmi.2022.12.012
553.
Temkin E, Margalit I, Nutman A, Carmeli Y. Surgical antibiotic prophylaxis in patients colonized with multidrug-resistant Gram-negative bacteria: practical and conceptual aspects. Journal of Antimicrobial Chemotherapy. 2021;76(Supplement_1):i40-i46. doi:10.1093/jac/dkaa496
555.
Calderwood MS, Anderson DJ, Bratzler DW, Dellinger EP, Garcia-Houchins S, Maragakis LL, et al. Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update. Infection Control & Hospital Epidemiology. 2023;44(5):695-720. doi:10.1017/ice.2023.67
557.
McDonald M, Grabsch E, Marshall C, Forbes A. Single- versus multiple-dose antimicrobial prophylaxis for major surgery: a systematic review. Australian and New Zealand Journal of Surgery. 1998;68(6). doi:10.1111/j.1445-2197.1998.tb04785.x
558.
de Jonge SW, Boldingh QJJ, Solomkin JS, Dellinger EP, Egger M, Salanti G, et al. Effect of postoperative continuation of antibiotic prophylaxis on the incidence of surgical site infection: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2020;20(10):1182-1192. doi:10.1016/S1473-3099(20)30084-0
560.
He K, Nayak RB, Allori AC, Brighton BK, Cina RA, Ellison JS, et al. Correlation Between Postoperative Antimicrobial Prophylaxis Use and Surgical Site Infection in Children Undergoing Nonemergent Surgery. JAMA Surgery. 2022;157(12):1142-1151. doi:10.1001/jamasurg.2022.4729
561.
Branch-Elliman W, O’Brien W, Strymish J, Itani K, Wyatt C, Gupta K. Association of Duration and Type of Surgical Prophylaxis With Antimicrobial-Associated Adverse Events. JAMA Surgery. 2019;154(7):590-598. doi:10.1001/jamasurg.2019.0569
562.
Royal College of Obstetricians & Gynaecologists. The Care of Women Requesting Induced Abortion (Evidence-Based Clinical Guideline No. 7). Published online November 2011. Accessed December 20, 2024. https://www.rcog.org.uk/media/nwcjrf0o/abortion-guideline_web_1.pdf
563.
Kovaleva J, Peters FTM, Mei HC van der, Degener JE. Transmission of infection by flexible gastrointestinal endoscopy and bronchoscopy. Clinical Microbiology Reviews. 2013;26(2):231-254. doi:10.1128/CMR.00085-12
564.
Fraser TG, Reiner S, Malczynski M, Yarnold PR, Warren J, Noskin GA. Multidrug-resistant Pseudomonas aeruginosa cholangitis after endoscopic retrograde cholangiopancreatography: failure of routine endoscope cultures to prevent an outbreak. Infection Control & Hospital Epidemiology. 2004;25(10):856-859. doi:10.1086/502309
565.
Nelson RL, Gladman E, Barbateskovic M. Antimicrobial prophylaxis for colorectal surgery. Cochrane Database of Systematic Reviews. 2014;2015(8). doi:10.1002/14651858.cd001181.pub4
566.
Chen M, Song X, Chen L, Lin Z, Zhang X. Comparing mechanical bowel preparation with both oral and systemic antibiotics versus mechanical bowel preparation and systemic antibiotics alone for the prevention of surgical site infection after elective colorectal surgery: a meta-analysis of randomized controlled clinical trials. Diseases of the Colon & Rectum. 2016;59(1):70-78. doi:10.1097/DCR.0000000000000524
567.
Kiran RP, Murray AC, Chiuzan C, Estrada D, Forde K. Combined preoperative mechanical bowel preparation with oral antibiotics significantly reduces surgical site infection, anastomotic leak, and ileus after colorectal surgery. Annals of Surgery. 2015;262(3):416-25; discussion 423-425. doi:10.1097/SLA.0000000000001416
568.
Morris MS, Graham LA, Chu DI, Cannon JA, Hawn MT. Oral antibiotic bowel preparation significantly reduces surgical site infection rates and readmission rates in elective colorectal surgery. Annals of Surgery. 2015;261(6):1034-1040. doi:10.1097/SLA.0000000000001125
569.
Chiu PKF, Kasivisvanathan V, Gandaglia G, European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Moving the Needle: Antibiotic Prophylaxis Is No Longer Required in the Era of Transperineal Prostate Biopsy. European Urology. 2023;84(2):154-155. doi:10.1016/j.eururo.2023.04.007
570.
Szabo RJ. Free-Hand Transperineal Prostate Biopsy Under Local Anesthesia in the Office Without Antibiotic Prophylaxis: Experience with 304 Cases. Journal of Endourology. 2021;35(4):518-524. doi:10.1089/end.2020.1086
571.
Jacewicz M, Günzel K, Rud E, Sandbæk G, Magheli A, Busch J, et al. Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial. The Lancet Infectious Diseases. 2022;22(10):1465-1471. doi:10.1016/s1473-3099(22)00373-5
572.
Benway BM. Prostate biopsy - UpToDate. Accessed December 20, 2024. https://www.uptodate.com/contents/prostate-biopsy/print
573.
The National Surgical Antibiotic Prophylaxis (SAP) Guideline Development Workgroup of the National Antimicrobial Stewardship Expert Panel (NASEP). National Surgical Antibiotic Prophylaxis Guideline (Singapore). Published online September 2022. https://www.ncid.sg/Health-Professionals/Documents
/NationalSAPGuidelineSingapore.pdf
574.
Pilatz A, Dimitropoulos K, Veeratterapillay R, Yuan Y, Omar MI, MacLennan S, et al. Antibiotic prophylaxis for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis. The Journal of Urology. 2020;204(2):224-230. doi:10.1097/JU.0000000000000814
575.
Basourakos SP, Alshak MN, Lewicki PJ, Cheng E, Tzeng M, DeRosa AP, et al. Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis. European Urology Open Science. 2022;37:53-63. doi:10.1016/j.euros.2022.01.001
576.
Baba K, Sekine Y, Miyazawa Y, Syuto T, Nomura M, Koike H, et al. Assessment of antimicrobial prophylaxis in transperineal prostate biopsy: A single-center retrospective study of 485 cases. Journal of Infection and Chemotherapy. 2018;24(8):637-640. doi:10.1016/j.jiac.2018.03.014
577.
Mian BM, Feustel PJ, Aziz A, Kaufman RP, Bernstein A, Avulova S, et al. Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial. The Journal of Urology. 2024;211(2):205-213. doi:10.1097/JU.0000000000003788
578.
Bloomfield MG, Wilson AD, Studd RC, Blackmore TK. Highly effective prophylaxis with ertapenem for transrectal ultrasound-guided prostate biopsy: effects on overall antibiotic use and inpatient hospital exposure. Journal of Hospital Infection. 2020;106(3):483-489. doi:10.1016/j.jhin.2020.08.020
579.
Bloomfield MG, Page MJ, McLachlan AG, Studd RC, Blackmore TK. Routine Ertapenem Prophylaxis for Transrectal Ultrasound Guided Prostate Biopsy does Not Select for Carbapenem Resistant Organisms: A Prospective Cohort Study. The Journal of Urology. 2017;198(2):362-368. doi:10.1016/j.juro.2017.03.077
580.
Pruthi DK, Liss MA. Sepsis: Prophylactic antibiotic for prostate biopsy: the carbapenem gamble. Nature Reviews Urology. 2017;14(7):394-396. doi:10.1038/nrurol.2017.73
581.
Bloomfield M, Blackmore T. Prophylactic ciprofloxacin for prostate biopsy: a losing bet? Nature Reviews Urology. 2017;14(11):696. doi:10.1038/nrurol.2017.154
582.
Rafiq M, Farag F, Manley K, Ho E. Ciprofloxacin: single versus multiple doses in transrectal ultrasound guided prostate biopsy. Central European Journal of Urology. 2020;73(1):91-93. doi:10.5173/ceju.2020.0067
583.
Chan ESY, Lo KL, Ng CF, Hou SM, Yip SK. Randomized controlled trial of antibiotic prophylaxis regimens for transrectal ultrasound-guided prostate biopsy. Chinese Medical Journal. 2012;125(14):2432-2435. doi:10.3760/cma.j.issn.0366-6999.2012.14.006
584.
Cheng KC, Lam WC, Chan HC, Ngo CC, Cheung MH, So HS, et al. Emergency attendances and hospitalisations for complications after transrectal ultrasound-guided prostate biopsies: a five-year retrospective multicentre study. Hong Kong Medical Journal. 2019;25(5):349-355. doi:10.12809/hkmj197825
585.
Bovo A, Kwiatkowski M, Manka L, Wetterauer C, Fux CA, Cattaneo M, et al. Comparison of ciprofloxacin versus fosfomycin versus fosfomycin plus trimethoprim/sulfamethoxazole for preventing infections after transrectal prostate biopsy. World Journal of Urology. 2024;42(1):356. doi:10.1007/s00345-024-05048-4
586.
Cussans A, Somani BK, Basarab A, Dudderidge TJ. The role of targeted prophylactic antimicrobial therapy before transrectal ultrasonography-guided prostate biopsy in reducing infection rates: a systematic review. BJU International. 2016;117(5):725-731. doi:10.1111/bju.13402
587.
Tsu JH, Ma WK, Chan WK, Lam BH, To KC, To WK, et al. Prevalence and predictive factors of harboring fluoroquinolone-resistant and extended-spectrum β-lactamase-producing rectal flora in Hong Kong Chinese men undergoing transrectal ultrasound-guided prostate biopsy. Urology. 2015;85(1):15-22. doi:10.1016/j.urology.2014.07.078
588.
NHS Greater Glasgow and Clyde. Antibiotic Prophylaxis for Urological Surgery and Procedures. Published online February 2024. https://rightdecisions.scot.nhs.uk/media/1rwcpzpn
/v6-049-antibiotic-prophylaxis-for-urological-surgery-24.pdf
589.
NHS Lanarkshire. Adult Antibiotic Prophylaxis in Urological Surgery. Published online May 2024. https://rightdecisions.scot.nhs.uk/media/2372
/adult-antibiotic-prophylaxis-in-urological-surgery-extended-may-24.pdf
590.
Lam HM, Wong HL, Lai TCT, Tsang CF, Ho BSH, Ng ATL. Comparison of incidence of post-TRUS prostate biopsy infection with different prophylactic antibiotics regimens. BJU International. 2024;133(S2):4-28. doi:10.1111/bju.16266
591.
Till SR, Morgan DM, Bazzi AA, Pearlman MD, Abdelsattar Z, Campbell DA, et al. Reducing surgical site infections after hysterectomy: metronidazole plus cefazolin compared with cephalosporin alone. American Journal of Obstetrics and Gynecology. 2017;217(2):187.e1-187.e11. doi:10.1016/j.ajog.2017.03.019
592.
Ayeleke RO, Mourad S, Marjoribanks J, Calis KA, Jordan V. Antibiotic prophylaxis for elective hysterectomy. Cochrane Database of Systematic Reviews. 2017;2019(5). doi:10.1002/14651858.cd004637.pub2
593.
Kobayashi T, Jenn KE, Bowdler N, Malloy R, Holley S, Izakovic T, et al. Reduction in abdominal hysterectomy surgical site infection rates after the addition of anaerobic antimicrobial prophylaxis. Infection Control & Hospital Epidemiology. 2020;41(12):1469-1471. doi:10.1017/ice.2020.386
594.
Tita ATN, Rouse DJ, Blackwell S, Saade GR, Spong CY, Andrews WW. Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systematic review. Obstetrics & Gynecology. 2009;113(3):675-682. doi:10.1097/AOG.0b013e318197c3b6
595.
Smaill FM, Grivell RM. Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section. Cochrane Database of Systematic Reviews. 2014;(10):CD007482. doi:10.1002/14651858.CD007482.pub3
596.
Mackeen AD, Packard RE, Ota E, Berghella V, Baxter JK. Timing of intravenous prophylactic antibiotics for preventing postpartum infectious morbidity in women undergoing cesarean delivery. Cochrane Database of Systematic Reviews. 2014;(12):CD009516. doi:10.1002/14651858.CD009516.pub2
597.
Liabsuetrakul T, Choobun T, Peeyananjarassri K, Islam QM. Antibiotic prophylaxis for operative vaginal delivery. Cochrane Database of Systematic Reviews. 2020;3(3):CD004455. doi:10.1002/14651858.CD004455.pub5
598.
Murphy DJ, Strachan BK, Bahl R, Royal College of Obstetricians and Gynaecologists. Assisted vaginal birth: green-top guideline no. 26. BJOG: An International Journal of Obstetrics & Gynaecology. 2020;127(9):e70-e112. doi:10.1111/1471-0528.16092
602.
Low N, Mueller M, Van Vliet HA, Kapp N. Perioperative antibiotics to prevent infection after first-trimester abortion. Cochrane Database of Systematic Reviews. 2012;(3):CD005217. doi:10.1002/14651858.CD005217.pub2
603.
World Health Organization. Abortion Care: Guidelines. World Health Organization; 2022. https://www.who.int/publications/i/item/9789240039483
604.
Patel PN, Jayawardena ADL, Walden RL, Penn EB, Francis DO. Evidence-Based Use of Perioperative Antibiotics in Otolaryngology. Otolaryngology–Head and Neck Surgery. 2018;158(5):783-800. doi:10.1177/0194599817753610
605.
Dhiwakar M, Eng CY, Selvaraj S, McKerrow WS. Antibiotics to improve recovery following tonsillectomy: a systematic review. Otolaryngology–Head and Neck Surgery. 2006;134(3):357-364. doi:10.1016/j.otohns.2005.12.016
606.
Dhiwakar M, Clement WA, Supriya M, McKerrow W. Antibiotics to reduce post-tonsillectomy morbidity. Cochrane Database of Systematic Reviews. 2012;12(12):CD005607. doi:10.1002/14651858.CD005607.pub4
607.
Pan IW, Kuo GM, Luerssen TG, Lam SK. Impact of antibiotic prophylaxis for intrathecal baclofen pump surgery in pediatric patients. Neurosurgical focus. 2015;39(6):E10. doi:10.3171/2015.9.FOCUS15385
608.
Hospenthal DR, Murray CK, Andersen RC, Bell RB, Calhoun JH, Cancio LC, et al. Guidelines for the prevention of infections associated with combat-related injuries: 2011 update: endorsed by the Infectious Diseases Society of America and the Surgical Infection Society. Journal of Trauma and Acute Care Surgery. 2011;71(2 Suppl 2):S210-34. doi:10.1097/TA.0b013e318227ac4b
609.
Hauser CJ, Adams CAJ, Eachempati SR. Surgical Infection Society guideline: prophylactic antibiotic use in open fractures: an evidence-based guideline. Surgical Infections. 2006;7(4):379-405. doi:10.1089/sur.2006.7.379
610.
Hoff WS, Bonadies JA, Cachecho R, Dorlac WC. East Practice Management Guidelines Work Group: update to practice management guidelines for prophylactic antibiotic use in open fractures. Journal of Trauma and Acute Care Surgery. 2011;70(3):751-754. doi:10.1097/TA.0b013e31820930e5
611.
Lack WD, Karunakar MA, Angerame MR, Seymour RB, Sims S, Kellam JF, et al. Type III open tibia fractures: immediate antibiotic prophylaxis minimizes infection. Journal of Orthopaedic Trauma. 2015;29(1):1-6. doi:10.1097/BOT.0000000000000262
612.
Gallagher M, Jones DJ, Bell-Syer SV. Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. Cochrane Database of Systematic Reviews. 2019;9(9):CD005360. doi:10.1002/14651858.CD005360.pub5
613.
Lui L. Hospital Authority Standard Report for the Clostridium difficile Surveillance Programme. Published online December 2023. Accessed December 20, 2024. https://icidportal.ha.org.hk/Home/File?path=%2FTraining
+Calendar%2F182%2FInitiating+surveillance+in+public+hospitals+in+Hong
+Kong.pdf
614.
Goldman AH, Tetsworth K. AAOS clinical practice guideline summary: prevention of surgical site infection after major extremity trauma. Journal of the American Academy of Orthopaedic Surgeons. 2023;31(1):e1-e8. doi:10.5435/JAAOS-D-22-00792
615.
Wolfhagen N, Boldingh QJJ, Lange M de, Boermeester MA, Jonge SW de. Intraoperative Redosing of Surgical Antibiotic Prophylaxis in Addition to Preoperative Prophylaxis Versus Single-dose Prophylaxis for the Prevention of Surgical Site Infection: A Meta-analysis and GRADE Recommendation. Annals of Surgery. 2022;275(6):1050-1057. doi:10.1097/SLA.0000000000005436
616.
Sartelli M, Boermeester MA, Cainzos M, Coccolini F, Jonge SW de, Rasa K, et al. Six long-standing questions about antibiotic prophylaxis in surgery. Antibiotics. 2023;12(5):908. doi:10.3390/antibiotics12050908
617.
Brocard E, Reveiz L, Régnaux JP, Abdala V, Ramón-Pardo P, Del Rio Bueno A. Antibiotic prophylaxis for surgical procedures: a scoping review. Pan American Journal of Public Health. 2021;45:e62. doi:10.26633/RPSP.2021.62
618.
Broom J, Broom A, Anstey C, Kenny K, Young S, Grieve D, et al. Barriers-enablers-ownership approach: a mixed methods analysis of a social intervention to improve surgical antibiotic prescribing in hospitals. BMJ Open. 2021;11(5):e046685. doi:10.1136/bmjopen-2020-046685
619.
The American Society of Breast Surgeons. Consensus Guideline on Preoperative Antibiotics and Surgical Site Infection in Breast Surgery. Published online June 2017. https://www.breastsurgeons.org/docs/statements
/asbrs-ccs-preoperative-antibiotics-and-surgical-site-infection.pdf
620.
Alderman A, Gutowski K, Ahuja A, Gray D, Postmastectomy Expander/Implant Breast Reconstruction Guideline Work Group. ASPS clinical practice guideline summary on breast reconstruction with expanders and implants. Plastic and Reconstructive Surgery. 2014;134(4):648e-655e. doi:10.1097/PRS.0000000000000541
621.
Gahm J, Ljung Konstantinidou A, Lagergren J, Sandelin K, Glimåker M, Johansson H, et al. Effectiveness of Single vs Multiple Doses of Prophylactic Intravenous Antibiotics in Implant-Based Breast Reconstruction: A Randomized Clinical Trial. JAMA Network Open. 2022;5(9):e2231583. doi:10.1001/jamanetworkopen.2022.31583
622.
Prantl L, Momeni A, Brebant V, Kuehlmann B, Heine N, Biermann N, et al. Recommendations for the use of antibiotics in primary and secondary esthetic breast surgery. Plastic and Reconstructive Surgery–Global Open. 2020;8(1):e2590. doi:10.1097/GOX.0000000000002590
623.
Association of Breast Surgery. ABS Summary Statement: Guidelines on antibiotic prophylaxis in breast surgery. Association of Breast Surgery. Published online January 2015. Accessed December 20, 2024. https://associationofbreastsurgery.org.uk/professionals/information-hub
/guidelines/2015
/abs-summary-statement-guidelines-on-antibiotic-prophylaxis-in-breast-surgery
624.
Orelio CC, Hessen C van, Sanchez-Manuel FJ, Aufenacker TJ, Scholten RJ. Antibiotic prophylaxis for prevention of postoperative wound infection in adults undergoing open elective inguinal or femoral hernia repair. Cochrane Database of Systematic Reviews. 2020;4(4):CD003769. doi:10.1002/14651858.CD003769.pub5
625.
Peel TN, Astbury S, Cheng AC, Paterson DL, Buising KL, Spelman T, et al. Trial of Vancomycin and Cefazolin as Surgical Prophylaxis in Arthroplasty. The New England Journal of Medicine. 2023;389(16):1488-1498. doi:10.1056/NEJMoa2301401
626.
National Collaborating Centre for Women’s and Children’s Health (UK). Surgical Site Infection: Prevention and Treatment of Surgical Site Infection. RCOG Press; 2008. Accessed December 20, 2024. http://www.ncbi.nlm.nih.gov/books/NBK53731
627.
Fairbanks DNF. Pocket Guide to Antimicrobial Therapy in Otolaryngology–Head and Neck Surgery. American Academy of Otolaryngology–Head & Neck Surgery Foundation, Inc.; 2007.
628.
Holtom PD. Antibiotic prophylaxis: current recommendations. Journal of the American Academy of Orthopaedic Surgeons. 2006;14(10):S98-S100. doi:10.5435/00124635-200600001-00023
629.
Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery. Obstetrics & Gynecology. 2018;132(3):e103-e119. doi:10.1097/AOG.0000000000002833
630.
Prokuski L. Prophylactic antibiotics in orthopaedic surgery. The Journal of the American Academy of Orthopaedic Surgeons. 2008;16(5):283-293. doi:10.5435/00124635-200805000-00007
631.
Koc M, Zulfikaroglu B, Kece C, Ozalp N. A prospective randomized study of prophylactic antibiotics in elective laparoscopic cholecystectomy. Surgical Endoscopy. 2003;17(11):1716-1718. doi:10.1007/s00464-002-8866-y
632.
Bratzler DW, Houck PM, Surgical Infection Prevention Guideline Writers Workgroup. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. The American Journal of Surgery. 2005;189(4):395-404. doi:10.1016/j.amjsurg.2005.01.015
633.
Higgins A, London J, Charland S, Ratzer E, Clark J, Haun W, et al. Prophylactic antibiotics for elective laparoscopic cholecystectomy: are they necessary? Archives of Surgery. 1999;134(6):611-614. doi:10.1001/archsurg.134.6.611
634.
Chang WT, Lee KT, Chuang SC, Wang SN, Kuo KK, Chen JS, et al. The impact of prophylactic antibiotics on postoperative infection complication in elective laparoscopic cholecystectomy: a prospective randomized study. The American Journal of Surgery. 2006;191(6):721-725. doi:10.1016/j.amjsurg.2006.01.050
635.
Kallen AJ, Wilson CT, Larson RJ. Perioperative intranasal mupirocin for the prevention of surgical-site infections: systematic review of the literature and meta-analysis. Infection Control & Hospital Epidemiology. 2005;26(12):916-922. doi:10.1086/505453
636.
Tan J, Ryan ÉJ, Davey MG, McHugh FT, Creavin B, Whelan MC, et al. Mechanical bowel preparation and antibiotics in elective colorectal surgery: network meta-analysis. BJS Open. 2023;7(3):zrad040. doi:10.1093/bjsopen/zrad040
637.
Güenaga KF, Matos D, Wille-Jørgensen P. Mechanical bowel preparation for elective colorectal surgery. Cochrane Database of Systematic Reviews. Published online September 2011. doi:10.1002/14651858.cd001544.pub4
638.
Buckman SA, Forrester JD, Bessoff KE, Parli SE, Evans HL, Huston JM. Surgical Infection Society Guidelines: 2022 Updated Guidelines for Antibiotic Use in Open Extremity Fractures. Surgical Infections. 2022;23(9):817-828. doi:10.1089/sur.2022.206
639.
Schweizer M, Perencevich E, McDanel J, Carson J, Formanek M, Hafner J, et al. Effectiveness of a bundled intervention of decolonization and prophylaxis to decrease Gram positive surgical site infections after cardiac or orthopedic surgery: systematic review and meta-analysis. BMJ. 2013;346. doi:10.1136/bmj.f2743
640.
Bebko SP, Green DM, Awad SS. Effect of a preoperative decontamination protocol on surgical site infections in patients undergoing elective orthopedic surgery with hardware implantation. JAMA Surgery. 2015;150(5):390-395. doi:10.1001/jamasurg.2014.3480
641.
NHS Tayside Antimicrobial Management Group/Surgical Directorate. Antibiotic Prophylaxis in General Surgery. Published online September 2019. https://www.nhstaysideadtc.scot.nhs.uk/Antibiotic%20site/pdf%20docs
/Antibiotic%20prophylaxis%20in%20gen%20surgery.pdf
642.
SA Health, the Government of South Australia. Surgical Antimicrobial Prophylaxis Prescribing Guideline. Published online December 2021. Accessed December 20, 2024. https://www.sahealth.sa.gov.au/wps/wcm/connect
/6bb523804358edbd883b9ef2cadc00ab/Surgical+Prophylaxis+Antimicrobial
+guideline+3.0+FINAL+March+2022.pdf
643.
Institute for Healthcare Improvement. How-to Guide: Prevent Surgical Site Infections. Published online 2012. https://www.urotoday.com/images/catheters/pdf/IHIHowtoGuidePreventSSI.pdf
644.
Nichols RL. Preventing Surgical Site Infections: A Surgeon’s Perspective. Emerging Infectious Diseases. 2001;7(2):220-224. doi:10.3201/eid0702.010214
645.
Li PH, Yeung HHF, Lau CS, Au EYL. Prevalence, Incidence, and Sensitization Profile of β-lactam Antibiotic Allergy in Hong Kong. JAMA Network Open. 2020;3(5):e204199. doi:10.1001/jamanetworkopen.2020.4199
646.
Li PH, Siew LQC, Thomas I, Watts TJ, Ue KL, Rutkowski K, et al. Beta-lactam allergy in Chinese patients and factors predicting genuine allergy. The World Allergy Organization Journal. 2019;12(8):100048. doi:10.1016/j.waojou.2019.100048
647.
Siew LQC, Li PH, Watts TJ, Thomas I, Ue KL, Caballero MR, et al. Identifying low-risk beta-lactam allergy patients in a UK tertiary centre. The Journal of Allergy and Clinical Immunology: In Practice. 2019;7(7):2173-2181. doi:10.1016/j.jaip.2019.03.015
648.
Mak HWF, Yeung MHY, Wong JCY, Chiang V, Li PH. Differences in beta-lactam and penicillin allergy: Beyond the West and focusing on Asia-Pacific. Frontiers in Allergy. 2022;3:1059321. doi:10.3389/falgy.2022.1059321
649.
Chiang V, Kan AKC, Saha C, Au EYL, Li PH. Identifying the most at-risk age-group and longitudinal trends of drug allergy labeling amongst 7.3 million individuals in Hong Kong. BMC Medicine. 2024;22(1):30. doi:10.1186/s12916-024-03250-0
650.
Wong JC, Au EY, Yeung HH, Lau CS, Li PH. Piperacillin-Tazobactam Allergies: An Exception to Usual Penicillin Allergy. Allergy, Asthma & Immunology Research. 2021;13(2):284-294. doi:10.4168/aair.2021.13.2.284
651.
Shi W, Liu N, Huang J, Xiao H, Meng J, Li PH. Penicillin Allergy in China: Consequences of Inappropriate Skin Testing Practices and Policies. Clinical & Experimental Allergy. Published online 2024. doi:10.1111/cea.14546
652.
Li TS, Hui HKS, Kan AKC, Yeung MHY, Wong JCY, Chiang V, et al. Prospective Assessment of Penicillin Allergy (PAPA): Evaluating the performance of penicillin allergy testing and post-delabelling outcomes among Hong Kong Chinese. Asian Pacific Journal of Allergy and Immunology. Published online April 2023. doi:10.12932/AP-270922-1469
653.
Mak HWF, Chan ETS, Yim JSH, Lee E, Lam DLY, Chiang V, et al. Validation of the Chinese drug hypersensitivity quality of life questionnaire: role of delabeling. Asia Pacific Allergy. 2023;13(1):3-9. doi:10.5415/apallergy.0000000000000020
654.
Wong JCY, Li PH. Drug allergy management in the elderly. Current Opinion in Allergy and Clinical Immunology. 2021;21(4):340-345. doi:10.1097/ACI.0000000000000761
655.
Li PH, Chung HY, Lau CS. Epidemiology and outcomes of geriatric and non-geriatric patients with drug allergy labels in Hong Kong. Hong Kong Medical Journal. 2021;27(3):192-197. doi:10.12809/hkmj208716
656.
Chan SCW, Yeung WWY, Wong JCY, Chui ESH, Lee MSH, Chung HY, et al. Prevalence and impact of reported drug allergies among rheumatology patients. Diagnostics. 2020;10(11):918. doi:10.3390/diagnostics10110918
657.
Li PH, Thong BYH, Pawankar R, Jeewandara C, Lobo RCM, Kang HR, et al. APAAACI clinical pathway on direct provocation testing for penicillin allergy delabeling. Asia Pacific Allergy. 2023;13(4):142-147. doi:10.5415/apallergy.0000000000000122
658.
Li PH, Wong JCY, Chan JMC, Chik TSH, Chu MY, Ho GCH, et al. Hong Kong Drug Allergy Delabelling Initiative (HK-DADI) consensus statements for penicillin allergy testing by nonallergists. Frontiers in Allergy. 2022;3:974138. doi:10.3389/falgy.2022.974138
659.
Lucas M, Mak HWF, Lee JTY, Kulkarni R, Chan SSC, Li PH. Impact of a drug allergy education course for non-specialists: Findings from ADAPT-A randomized crossover trial. Allergy. Published online August 2024. doi:10.1111/all.16270
660.
Kan AKC, Hui HKS, Li TS, Chiang V, Wong JCY, Chan TS, et al. Comparative Effectiveness, Safety, and Real-World Outcomes of a Nurse-Led, Protocol-Driven Penicillin Allergy Evaluation From the Hong Kong Drug Allergy Delabelling Initiative (HK-DADI). The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(2):474-480.e2. doi:10.1016/j.jaip.2022.08.052
661.
Wong JCY, Kan AKC, Chik TSH, Chu MY, Li TCM, Mak HWF, et al. Prospective, Multicenter, Head-to-Head Comparison Between Allergists Versus Nonallergists in Low-Risk Penicillin Allergy Delabeling: Effectiveness, Safety, and Quality of Life (HK-DADI2). The Journal of Allergy and Clinical Immunology: In Practice. 2024;12(7):1801-1808.e2. doi:10.1016/j.jaip.2024.04.010
662.
Picard M, Robitaille G, Karam F, Daigle JM, Bédard F, Biron É, et al. Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses. The Journal of Allergy and Clinical Immunology: In Practice. 2019;7(8):2722-2738.e5. doi:10.1016/j.jaip.2019.05.038
663.
DePestel DD, Benninger MS, Danziger L, LaPlante KL, May C, Luskin A, et al. Cephalosporin use in treatment of patients with penicillin allergies. Journal of the American Pharmacists Association. 2008;48(4):530-540. doi:10.1331/JAPhA.2008.07006